  <page>
    <title>N,N-Dimethyltryptamine</title>
    <ns>0</ns>
    <id>8748</id>
    <revision>
      <id>943149959</id>
      <parentid>943148669</parentid>
      <timestamp>2020-02-29T04:19:53Z</timestamp>
      <contributor>
        <username>Bawanio</username>
        <id>37693503</id>
      </contributor>
      <minor />
      <comment>/* Society and culture */</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve">{{short description|Chemical compound}}
{{More medical citations needed|date=June 2017}}
{{DISPLAYTITLE:''N'',''N''-Dimethyltryptamine}}
{{Drug
| Watchedfields = changed
| drug_name = ''N'',''N''-Dimethyltryptamine
| verifiedrevid = 623685269
| IUPAC_name = 2-(1''H''-Indol-3-yl)-''N'',''N''-dimethylethanamine
| image = DMT.svg
| width = 200
| image2 = Dimethyltryptamine_27feb.gif
| width2 = 200

&lt;!--Clinical data--&gt;
| legal_AU = S9
| legal_CA = Schedule III
| legal_UK = Class A
| legal_US = Schedule I
| legal_DE = Anlage I
| legal_UN = Psychotropic Schedule I
| routes_of_administration = Oral (with an [[monoamine oxidase inhibitor|MAOI]]), [[insufflation (medicine)|insufflated]], [[Rectal (medicine)|rectal]], [[Vaporization|vaporized]], [[Intramuscular injection|IM]], [[intravenous injection|IV]]

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 61-50-7
| ATC_prefix = none
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01488
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = WUB601BHAA
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 28969
| PubChem = 6089
| IUPHAR_ligand = 141
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5864
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C08302
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 12420

&lt;!--Chemical data--&gt;
| C=12 | H=16 | N=2
| molecular_weight = 188.269
| smiles = CN(CCC1=CNC2=C1C=CC=C2)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DMULVCHRPCFFGV-UHFFFAOYSA-N
| density = 1.099
| melting_point = 40
| boiling_point = 160
| boiling_notes = @&amp;nbsp;{{convert|0.6|Torr|Pa|abbr=on}}&lt;ref&gt;{{Cite journal |title=Untersuchungen zur Trifluoracetylierung der Methylderivate von Tryptamin und Serotonin mit verschiedenen Derivatisierungsreagentien: Synthesen, Spektroskopie sowie analytische Trennungen mittels Kapillar-GC |trans-title=Trifluoracetylation of methylated derivatives of tryptamine and serotonin by different reagents: synthesis, spectroscopic characterizations, and separations by capillary-gas-chromatography |year=1999 |journal=Zeitschrift für Naturforschung B |volume=54 |issue=3 |pages=397–414 |last1=Häfelinger |first1 =G. |last2= Nimtz |first2= M. |last3= Horstmann |first3=V. |last4=Benz |first4=T.|doi=10.1515/znb-1999-0319 }}&lt;/ref&gt;&lt;br/&gt;also reported as&lt;br/&gt;{{convert|80|-|135|C}} @&amp;nbsp;{{convert|0.03|Torr|Pa|abbr=on}}&lt;ref&gt;{{cite journal |last1=Corothie |first1=E |last2=Nakano |first2=T |author9=E. Corothie, T. Nakano |title=Constituents of the bark of ''Virola sebifera'' |journal=Planta Medica |year=1969 |volume=17 |issue=2 |pages=184–188 |doi=10.1055/s-0028-1099844 |pmid=5792479}}&lt;/ref&gt;
}}
{{Psychedelic sidebar}}
'''''N'',''N''-Dimethyltryptamine''' ('''DMT''' or '''''N'',''N''-DMT''') is a [[chemical substance]] that occurs in many plants and animals and which is both a [[derivative (chemistry)|derivative]] and a [[structural analog]] of [[tryptamine]].&lt;ref&gt;{{cite journal |last1=Carbonaro |first1=Theresa M. |last2=Gatch |first2=Michael B. |title=Neuropharmacology of ''N'',''N''-dimethyltryptamine |journal=Brain Research Bulletin |date=September 2016 |volume= 126|issue=Pt. 1 |pages=74–88 |doi=10.1016/j.brainresbull.2016.04.016 |pmid=27126737 |pmc=5048497}}&lt;/ref&gt; It can be consumed as a [[psychedelic drug]] and has historically been prepared by various cultures for [[ritual]] purposes as an [[entheogen]].&lt;ref name=&quot;pmid6587171&quot;&gt;{{cite journal |last2=Towers |first2=G. H. N. |last3=Abbott |first3=F. |date=April 1984 |title=Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and ''β''-carboline constituents of ''ayahuasca'' |journal=Journal of Ethnopharmacology |volume=10 |issue=2 |pages=195–223 |doi=10.1016/0378-8741(84)90003-5 |issn=0378-8741 |pmid=6587171 |last1=McKenna |first1=Dennis J.}}&lt;/ref&gt; DMT is illegal in most countries.

DMT has a rapid onset, intense effects and a relatively short duration of action. For those reasons, DMT was known as the &quot;business trip&quot; during the 1960s in the United States, as a user could access the full depth of a [[psychedelic experience]] in considerably less time than with other substances such as [[Lysergic acid diethylamide|LSD]] or [[Psilocybin mushroom|magic mushrooms]].&lt;ref&gt;{{cite journal |title=Emerging Drugs of Abuse |date=November 2005 |last1=Haroz |first1=Rachel |last2=Greenberg |first2=Michael I. |journal=Medical Clinics of North America |volume=89 |issue=6 |pages=1259–76 |issn=0025-7125 |oclc=610327022 |doi=10.1016/j.mcna.2005.06.008 |pmid=16227062}}&lt;/ref&gt; DMT can be inhaled, ingested, or injected and its effects depend on the dose. When inhaled or injected, the effects last a short period of time: about 5 to 15 minutes. Effects can last three hours or more when orally ingested along with an [[Monoamine oxidase inhibitor|MAOI]], such as the [[Ayahuasca|ayahuasca brew]] of many native [[Amazon rainforest|Amazonian]] tribes.&lt;ref name=&quot;Pickover 2005&quot;&gt;{{cite book |title=Sex, Drugs, Einstein, and Elves: Sushi, Psychedelics, Parallel Universes, and the Quest for Transcendence |last=Pickover |first=Cliff |year=2005 |publisher=Smart Publications |isbn=978-1-890572-17-4 |url=https://archive.org/details/sexdrugseinstein00clif }}&lt;/ref&gt; DMT can produce vivid &quot;projections&quot; of [[mystical experiences]] involving euphoria and dynamic [[hallucination]]s of geometric forms.&lt;ref name=&quot;DMT_Erowid&quot;&gt;{{cite web |url=http://www.erowid.org/chemicals/dmt/dmt.shtml |title=Erowid DMT (Dimethyltryptamine) Vault |publisher=Erowid.org |date= |accessdate=2012-09-20}}&lt;/ref&gt;

DMT is a [[functional analog (chemistry)|functional analog]] and [[structural analog]] of other psychedelic tryptamines such as [[O-acetylpsilocin]] (4-AcO-DMT), [[5-MeO-DMT]], [[bufotenin]] (5-HO-DMT), [[psilocybin]] (4-PO-DMT), and [[psilocin]] (4-HO-DMT). The structure of DMT occurs within some important biomolecules like [[serotonin]] and [[melatonin]], making them structural analogs of DMT.

{{TOC limit}}

==Usage==
DMT is produced in many species of plants often in conjunction with its close chemical relatives 5-methoxy-''N'',''N''-dimethyltryptamine ([[5-MeO-DMT]]) and [[bufotenin]] (5-OH-DMT).&lt;ref name = &quot;ISBN 0789026422&quot;/&gt; DMT-containing plants are commonly used in [[Shamanism#Amazonia|indigenous Amazonian shamanic practices]]. It is usually one of the main active constituents of the drink [[ayahuasca]];&lt;ref name=&quot;RivierLindgren1972&quot;&gt;{{cite journal |last1=Rivier |first1=Laurent|last2=Lindgren|first2=Jan-Erik|title='Ayahuasca,' the South American hallucinogenic drink: An ethnobotanical and chemical investigation|journal=Economic Botany |volume=26|issue=2|year=1972|pages=101–129|issn=0013-0001|doi=10.1007/BF02860772}}&lt;/ref&gt;&lt;ref name=&quot;McKennaTowers1984&quot;&gt;{{cite journal|last1=McKenna|first1=Dennis J.|last2=Towers|first2=G.H.N.|last3=Abbott|first3=F.|title=Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca|journal=Journal of Ethnopharmacology |volume=10 |issue=2 |year=1984 |pages=195–223 |issn=0378-8741 |doi=10.1016/0378-8741(84)90003-5 |pmid=6587171}}&lt;/ref&gt; however, ayahuasca is sometimes brewed with plants that do not produce DMT. It occurs as the primary psychoactive [[alkaloid]] in several plants including ''[[Mimosa tenuiflora]]'', ''[[Diplopterys cabrerana]]'', and ''[[Psychotria viridis]]''. DMT is found as a minor alkaloid in snuff made from [[Virola]] bark resin in which [[5-MeO-DMT]] is the main active alkaloid.&lt;ref name = &quot;ISBN 0789026422&quot;/&gt; DMT is also found as a minor alkaloid in bark, pods, and beans of ''[[Anadenanthera peregrina]]'' and ''[[Anadenanthera colubrina]]'' used to make [[Yopo]] and [[Anadenanthera colubrina|Vilca]] snuff, in which bufotenin is the main active alkaloid.&lt;ref name=&quot;ISBN 0789026422&quot;&gt;{{cite book |title=Anadenanthera: Visionary Plant Of Ancient South America |last1=Torres |first1=Constantino Manuel |last2=Repke |first2=David B. |year=2006 |publisher=Haworth Herbal |location=Binghamton, NY |isbn=978-0-7890-2642-2 |pages=107–122}}&lt;/ref&gt;&lt;ref name=&quot;pmid11718320&quot;&gt;{{cite journal |author=Ott J. |title=Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine |journal=Journal of Psychoactive Drugs |volume=33 |issue=3 |pages=273–81 |year=2001 |pmid=11718320 |doi= 10.1080/02791072.2001.10400574|url=http://files.shroomery.org/attachments/8588382-pharmanopo_J_Ott_2001_J_Psych_Drug.pdf }}&lt;/ref&gt; [[Psilocin]] and its precursor [[psilocybin]], an active chemical in many [[psilocybin mushroom]]s, are structurally similar to DMT.

The psychotropic effects of DMT were first studied scientifically by the [[Hungary|Hungarian]] chemist and psychologist [[Stephen Szára]], who performed research with volunteers in the mid-1950s. Szára, who later worked for the US [[National Institutes of Health]], had turned his attention to DMT after his order for [[LSD]] from the [[Swiss]] company [[Sandoz Laboratories]] was rejected on the grounds that the powerful psychotropic could be dangerous in the hands of a communist country.&lt;ref name=&quot;strassman&quot;&gt;{{cite book|title=DMT: The Spirit Molecule. A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences|last=Strassman|first=Rick J.|publisher=Park Street|year=2001|isbn=978-0-89281-927-0|location=Rochester, VT|authorlink=Rick Strassman|url=https://archive.org/details/dmtspiritmolecul00rick}} ({{cite web|url=http://rickstrassman.com/index.php?option=com_content&amp;view=article&amp;id=61&amp;Itemid=60|title=Chapter summaries|accessdate=27 February 2012}})&lt;/ref&gt;

DMT is generally not active orally unless it is combined with a [[monoamine oxidase inhibitor]] (MAOI) such as a reversible inhibitor of monoamine oxidase A (RIMA), for example, [[harmaline]].&lt;ref name=&quot;pmid6587171&quot; /&gt; Without a MAOI, the body quickly metabolizes orally administered DMT, and it therefore has no hallucinogenic effect unless the dose exceeds monoamine oxidase's metabolic capacity. Other means of ingestion such as vaporizing, injecting, or [[Insufflation (medicine)|insufflating]] the drug can produce powerful hallucinations for a short time (usually less than half an hour), as the DMT reaches the brain before it can be metabolized by the body's natural monoamine oxidase. Taking a MAOI prior to vaporizing or injecting DMT prolongs and potentiates the effects.&lt;ref name=&quot;DMT_Erowid&quot;/&gt;

==Effects==
{{See also|Ayahuasca#Effects}}

===Subjective psychedelic experiences===
Several scientific experimental studies have tried to measure subjective experiences of altered states of consciousness induced by drugs under highly controlled and safe conditions.

In the 1990s, [[Rick Strassman]] and his colleagues conducted a five-year-long DMT study at the [[University of New Mexico]].&lt;ref name=&quot;pmid8297216&quot;&gt;{{cite journal |author1=Strassman R.J. |author2=Qualls C.R. |title=Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects |journal=Archives of General Psychiatry |volume=51 |issue=2 |pages=85–97 |date=February 1994 |pmid=8297216 |doi=10.1001/archpsyc.1994.03950020009001}}&lt;/ref&gt; The results provided insight about the quality of subjective psychedelic experiences. In this study participants received the DMT dosage intravenously via injection and the findings suggested that different psychedelic experiences can occur, depending on the level of dosage. Lower doses (0.01 and 0.05&amp;nbsp;mg/kg) produced somaesthetic and emotional responses, but not hallucinogenic experiences (e.g., 0.05&amp;nbsp;mg/kg had mild mood elevating and calming properties).&lt;ref name=&quot;pmid8297216&quot; /&gt; In contrast, responses produced by higher doses (0.2 and 0.4&amp;nbsp;mg/kg) researchers labeled as &quot;hallucinogenic&quot; that elicited &quot;intensely colored, rapidly moving display of visual images, formed, abstract or both&quot;. Comparing to other sensory modalities the most affected was visual domain. Participants reported visual hallucinations, less auditory hallucinations and specific physical sensation progressing to a sense of bodily dissociation, as well as experiences of euphoria, calm, fear, and anxiety.&lt;ref name=&quot;pmid8297216&quot; /&gt;

Strassman also stressed the importance of the context where the drug has been taken. He claimed that DMT has no beneficial effects of itself, rather the context when and where people take it plays an important role.&lt;ref name=&quot;strassman&quot; /&gt;&lt;ref name=&quot;pmid8297216&quot; /&gt;

It appears that DMT can produce a hallucinogenic experience. It can induce a state or feeling to a person that he or she is able to &quot;communicate with other intelligent-life forms&quot; (see [[#Reported encounters with external entities|&quot;Machine Elves&quot;]]). High doses of DMT produce a hallucinatory state that involves a sense of &quot;another intelligence&quot; that people sometimes describe as &quot;super-intelligent&quot;, but &quot;emotionally detached&quot;.&lt;ref name=&quot;pmid8297216&quot; /&gt;

In 1995 Adolf Dittrich and Daniel Lamparter did a study where they found that DMT-induced altered state of consciousness (ASC) is strongly influenced by habitual, rather than situative factors. In the study researchers used three dimensions of the [[APZ questionnaire]] to describe ASC (rating scales of ASC). First, oceanic boundlessness (OB) refers to [[ego death|dissolution of ego boundaries]] mostly associated with positive emotions.&lt;ref name=&quot;Dittrich&quot;&gt;{{cite journal|last1=Lamparter|first1=D.|last2=Dittrich|first2=A.|title=Intraindividuelle Stabilität von ABZ unter sensorischer Deprivation, N,N-Dimethyltryptamin (DMT) und Stickoxydul|journal=Yearbook of the European College for the Study of Consciousness|date=1995|pages=33–44}}&lt;/ref&gt; Second, anxious ego-dissolution (AED) includes disorder of thoughts, loss of autonomy and self-control and third, visionary restructuralization (VR) that includes auditory and visual illusions, hallucinations.&lt;ref&gt;{{cite journal|last1=Vollenweider|first1=F. X.|title=Brain mechanisms of hallucinogens and entactogens|journal=Dialogues in Clinical Neuroscience|date=2001|volume=3|issue=4|pages=265–279|pmid=22033605|pmc=3181663}}&lt;/ref&gt; Results showed strong effects within first and third dimensions for all conditions, especially DMT and suggested strong intrastability of elicited reactions independently of the condition for the OB and VR scales.&lt;ref name=&quot;Dittrich&quot; /&gt; Importantly, the experiment was conducted in a safe laboratory environment. This particular setting had a certain influence on found results that might be very different outside the laboratory environment.

Induced DMT experiences can include profound time-dilation, visual and auditory illusions, and other experiences that, by most firsthand accounts, defy verbal or visual description. Some users report intense erotic imagery and sensations and utilize the drug in a ritual sexual context.&lt;ref name=&quot;Peru&quot; /&gt;&lt;ref&gt;{{cite web | url=http://www.maps.org/news-letters/v12n1/12125set.html | title=2C-B, DMT, You and Me | accessdate=2007-01-13 | publisher=Maps}}&lt;/ref&gt;&lt;ref&gt;{{cite web | url=http://www.miqel.com/entheogens/psychedelics_entheogens.html | title=Entheogens &amp; Visionary Medicine Pages | accessdate=2007-08-17 | publisher=Miqel.com | url-status=dead | archiveurl=https://web.archive.org/web/20120308162757/http://www.miqel.com/entheogens/psychedelics_entheogens.html | archivedate=2012-03-08 | df= }}&lt;/ref&gt;

====Reported encounters with external entities====
{{anchor|Machine elves}}
Entities perceived during DMT inebriation have been represented in diverse forms of psychedelic art.&lt;ref&gt;{{cite web|url=https://kahpi.net/meeting-the-dmt-trip-entities-in-art/ |title=Meeting the DMT Trip Entities in Art |first=Des |last=Tramacchi | publisher=Kahpi |date=2018 |accessdate=2018-10-22}}&lt;/ref&gt; The term ''machine elf'' was coined by ethnobotanist [[Terence McKenna]] for the entities he encountered in DMT &quot;hyperspace&quot;, also using terms like ''fractal elves'', or ''self-transforming machine elves''.&lt;ref&gt;{{cite book |first=Rick |last=Strassman |title=Dmt: the Spirit Molecule: A Doctor's Revolutionary Research into the Biology of near-Death and Mystical Experiences |year=2001 |isbn=978-0-89281-927-0 |pages=[https://archive.org/details/dmtspiritmolecul00rick/page/187 187–8, also pp.173–4] |quote=I had expected to hear about some of these types of experiences once we began giving DMT. I was familiar with Terence McKenna's tales of the &quot;self-transforming machine elves&quot; he encountered after smoking high doses of the drug. Interviews conducted with twenty experienced DMT smokers before beginning the New Mexico research also yielded some tales of similar meetings with such entities. Since most of these people were from California, I admittedly chalked up these stories to some kind of West Coast eccentricity |url=https://archive.org/details/dmtspiritmolecul00rick/page/187 }}&lt;/ref&gt;&lt;ref&gt;{{cite book |title=The Invisible Landscape: Mind, Hallucinogens and the I Ching |first=Terence |last=McKenna |year=1975}}&lt;/ref&gt; McKenna first encountered the &quot;machine elves&quot; after smoking DMT in Berkeley in 1965. His subsequent speculations regarding the hyperdimensional space in which they were encountered have inspired a great many artists and musicians, and the meaning of DMT entities has been a subject of considerable debate among participants in a networked cultural underground, enthused by McKenna's effusive accounts of DMT hyperspace.&lt;ref&gt;Graham St John (2015). ''Mystery School in Hyperspace: A Cultural History of DMT,'' North Atlantic Books / Evolver. {{ISBN|1583947329}}. Berkeley, CA. chapters 4, 8, and 12.&lt;/ref&gt; [[Cliff Pickover]] has also written about the &quot;machine elf&quot; experience, in the book ''Sex, Drugs, Einstein, &amp; Elves'',&lt;ref name=&quot;Pickover 2005&quot; /&gt; while [[Rick Strassman]] notes many similarities between self-reports of his DMT study participants' encounters with these &quot;entities&quot;, and mythological descriptions of figures such as [[Angels in Judaism#Angelic hierarchy|Chayot Ha Kodesh]] in Ancient religions, including both angels and demons.&lt;ref name=&quot;Prophecy 2014&quot;&gt;''DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible'', Rick Strassman, (Simon and Schuster 2014)&lt;/ref&gt; Strassman also argues for a similarity in his study participants' descriptions of mechanized wheels, gears and machinery in these encounters, with those described in visions of encounters with the [[Living creatures (Bible)|Living Creatures]] and [[Ophanim]] of the Hebrew Bible, noting they may stem from a common [[Neuropsychopharmacology|neuropsychopharmacological]] experience.&lt;ref name=&quot;Prophecy 2014&quot;/&gt;

Strassman argues that the more positive of the &quot;external entities&quot; encountered in DMT experiences should be understood as analogous to certain forms of angels: {{quote|The medieval Jewish philosophers whom I rely upon for understanding the [[Hebrew Bible]] text and its concept of prophecy portray angels as God's intermediaries. That is, they perform a certain function for God. Within the context of my DMT research, I believe that the beings that volunteers see could be conceived of as angelic - that is, previously invisible, incorporeal spiritual forces that are engarbed or enclothed in a particular form - determined by the psychological and spiritual development of the volunteers - bringing a particular message or experience to that volunteer.&lt;ref&gt;[https://boingboing.net/2011/05/03/strassman.html Interview: Dr. Rick Strassman] / AVI SOLOMON / 6:39 AM TUE MAY 3, 2011&lt;/ref&gt;}}
However, Strassman's experimental participants also note that some other entities can subjectively resemble creatures more like insects and aliens.&lt;ref&gt;{{cite book |first=Rick |last=Strassman |title=Dmt: the Spirit Molecule: A Doctor's Revolutionary Research into the Biology of near-Death and Mystical Experiences |year=2001 |isbn=978-0-89281-927-0 |pages=[https://archive.org/details/dmtspiritmolecul00rick/page/206 206–208] |url=https://archive.org/details/dmtspiritmolecul00rick/page/206 }}&lt;/ref&gt; As a result, Strassman writes these experiences among his experimental participants &quot;also left me feeling confused and concerned about where the spirit molecule was leading us. It was at this point that I began to wonder if I was getting in over my head with this research.&quot;&lt;ref&gt;{{cite book |first=Rick |last=Strassman |title=Dmt: the Spirit Molecule: A Doctor's Revolutionary Research into the Biology of near-Death and Mystical Experiences |year=2001 |isbn=978-0-89281-927-0 |pages=[https://archive.org/details/dmtspiritmolecul00rick/page/202 202] |url=https://archive.org/details/dmtspiritmolecul00rick/page/202 }}&lt;/ref&gt;

Hallucinations of strange creatures had been reported by Stephen Szara in a 1958 study in psychotic patients, in which he described how one of his subjects under the influence of DMT had experienced &quot;strange creatures, dwarves or something&quot; at the beginning of a DMT trip.&lt;ref&gt;{{cite web |url=http://www.redicecreations.com/article.php?id=12496 |title=Causal Multiplicity: The Science Behind Schizophrenia |date=10 September 2010 |first=Micah A. |last=Hanks}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://www.buildingalienworlds.com/uploads/5/7/9/9/57999785/dmt_research_1956_edge_time_arg_dpl_final.pdf |title=DMT research from 1956 to the edge of time |date=15 December 2015 |author1=Gallimore A.R. |author2=Luke D.P.}}&lt;/ref&gt;

Other researchers of the entities seemingly encountered by DMT users describe them as &quot;entities&quot; or &quot;beings&quot; in humanoid as well as animal form, with descriptions of &quot;little people&quot; being common (non-human [[gnomes]], elves, [[imps]], etc.).&lt;ref name=&quot;Gallimore&quot;&gt;{{cite journal |vauthors=Gallimore, A |title=Evolutionary Implications of the Astonishing Psychoactive Effects of N,N-Dimethyltryptamine (DMT)|journal=[[Journal of Scientific Exploration]] |volume=27|issue=3|pages=455–503 |date=2013 |url=https://www.researchgate.net/publication/277281153}}{{rs?|date=February 2020}}&lt;/ref&gt; Strassman and others have speculated that this form of hallucination may be the cause of [[alien abduction]] and extraterrestrial encounter experiences, which may occur through [[Endogeny (biology)|endogenously]]-occurring DMT.&lt;ref&gt;{{cite journal |last=Luke |first=D. |year=2011 |title=Discarnate entities and dimethyltryptamine (DMT): Psychopharmacology, phenomenology and ontology |url=https://www.scribd.com/doc/70007742/Discarnate-Entities |journal=Journal of the Society for Psychical Research |volume=75 |number=902 |pages=26–42}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last=Luke |first=D. P. |year=2012 |title=Psychoactive substances and paranormal phenomena: A comprehensive review |url=http://www.transpersonalstudies.org/ImagesRepository/ijts/Downloads/Luke%20IJTS%2031(1)-2012.pdf |archive-url=https://web.archive.org/web/20131005121927/http://www.transpersonalstudies.org/ImagesRepository/ijts/Downloads/Luke%20IJTS%2031(1)-2012.pdf |url-status=dead |archive-date=2013-10-05 |journal=International Journal of Transpersonal Studies |volume=31 |pages=97–156 |doi=10.24972/ijts.2012.31.1.97 }}&lt;/ref&gt;

Likening them to descriptions of rattling and chattering auditory phenomenon described in encounters with the [[Angels in Judaism#Angelic hierarchy|Hayyoth]] in the [[Book of Ezekiel]], Rick Strassman notes that participants in his studies, when reporting encounters with the alleged entities, have also described loud auditory hallucinations, such as one subject reporting typically &quot;the elves laughing or talking at high volume, chattering, twittering&quot;.&lt;ref name=&quot;Prophecy 2014&quot;/&gt;

===Physiological response===
According to a dose-response study in human subjects, dimethyltryptamine administered [[intravenously]] slightly elevated blood pressure, heart rate, pupil diameter, and rectal temperature, in addition to elevating blood concentrations of beta-[[endorphin]], [[corticotropin]], [[cortisol]], and [[prolactin]]; [[growth hormone]] blood levels rise equally in response to all doses of DMT, and [[melatonin]] levels were unaffected.&quot;&lt;ref name=&quot;pmid8297216&quot; /&gt;

===Dependence liability===
The dependence potential of DMT and the risk of sustained psychological disturbance may be minimal when used infrequently, as in religious ceremonies; however, the physiological dependence potential of DMT and ayahuasca remains to be documented convincingly.&lt;ref&gt;{{cite journal |year=2007 |title=Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids |journal=Addiction |volume=102 |issue=1 |pages=24–34 |doi=10.1111/j.1360-0443.2006.01652.x |pmid=17207120 |author=Robert S. Gable |url=http://iceers.org/docs/science/ayahuasca/ayahuasca-paper-addiction-ja07.pdf |citeseerx=10.1.1.655.8494 |access-date=2017-10-24 |archive-url=https://web.archive.org/web/20171229041846/https://www.iceers.org/docs/science/ayahuasca/ayahuasca-paper-addiction-ja07.pdf |archive-date=2017-12-29 |url-status=dead }}&lt;/ref&gt;

===Conjecture regarding endogenous effects===
In the 1950s, the endogenous production of psychoactive agents was considered to be a potential explanation for the hallucinatory symptoms of some psychiatric diseases; this is known as the transmethylation hypothesis.&lt;ref name=&quot;pmid13152519&quot;&gt;{{cite journal |author1=Hoffer A. |author2=Osmond H. |author3=Smythies J. |title=Schizophrenia; a new approach. II. Result of a year's research |journal=Journal of Mental Science |volume=100 |issue=418 |pages=29–45 |date=January 1954 |pmid=13152519 |doi=10.1192/bjp.100.418.29 |url= }}&lt;/ref&gt; Several speculative and yet untested hypotheses suggest that [[endogenous]] DMT is produced in the human brain and is involved in certain psychological and neurological states.&lt;ref&gt;{{cite web | url=http://www.sbs.com.au/news/article/2013/11/08/dmt-drug-produced-our-brain | title=DMT: The psychedelic drug 'produced in your brain' | publisher=SBS | date=8 November 2013 | accessdate=27 March 2014}}&lt;/ref&gt; DMT is naturally occurring in small amounts in rat brain, human cerebrospinal fluid, and other tissues of humans and other mammals.&lt;ref name=&quot;pmid16095048&quot; /&gt;&lt;ref name=&quot;pmid289421&quot; /&gt;&lt;ref name=&quot;pmid20877&quot; /&gt;&lt;ref&gt;{{cite web|url=https://www.npr.org/templates/story/story.php?storyId=104240746&amp;sc=fb&amp;cc=fp |title=The God Chemical: Brain Chemistry And Mysticism |publisher=NPR |date= |accessdate=2012-09-20}}&lt;/ref&gt; In 2011, Nicholas V. Cozzi, of the [[University of Wisconsin School of Medicine and Public Health]], concluded that [[INMT]], an enzyme that may be associated with the biosynthesis of DMT and endogenous hallucinogens, is present in the primate (rhesus macaque) pineal gland, retinal ganglion neurons, and spinal cord.&lt;ref name=&quot;Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E. 2011 840.19&quot; /&gt; Neurobiologist Andrew Gallimore (2013) suggested that while DMT might not have a modern neural function, it may have been an ancestral neuromodulator once secreted in psychedelic concentrations during [[Rapid eye movement sleep|REM sleep]], a function now lost.&lt;ref name=&quot;Gallimore&quot; /&gt;

==Routes of administration==

=== Inhalation ===
A standard dose for vaporized DMT is 20–60&amp;nbsp;milligrams.&lt;ref&gt;{{cite web|url=https://erowid.org/chemicals/dmt/dmt_dose.shtml|title=DMT Dosage|website=[[Erowid]]|access-date=25 June 2018}}&lt;/ref&gt;{{unreliable source?|date=June 2018}} In general, this is inhaled in a few successive breaths. The effects last for a short period of time, usually 5 to 15 minutes, dependent on the dose. The onset after inhalation is very fast (less than 45 seconds) and peak effects are reached within a minute. In the 1960s, DMT was known as a &quot;business trip&quot; in the US because of the relatively short duration (and rapid onset) of action when inhaled.&lt;ref&gt;{{cite journal |title=Emerging Drugs of Abuse |date=November 2005 |last1=Haroz |first1=Rachel|last2=Greenberg|first2=Michael I. |journal=Medical Clinics of North America |volume=89 |issue=6 |pages=1259–76 |issn=0025-7125 |oclc=610327022 |doi=10.1016/j.mcna.2005.06.008 |pmid=16227062 |quote=Use of DMT was first encountered in the United States in the 1960s, when it was known as a 'businessman's trip' because of the rapid onset of action when smoked (2 to 5 minutes) and short duration of action (20 minutes to 1 hour).}}&lt;/ref&gt; DMT can be inhaled using a [[bong]] or even an [[e-cigarette]].&lt;ref&gt;{{cite web|url=https://www.mirror.co.uk/news/technology-science/technology/digital-druggies-turn-electronic-cigarettes-4928383|title=Digital druggies turn electronic cigarettes into 'psychedelic crack' pipes|last=Hamill|first=Jasper|website=[[Daily Mirror]]|access-date=6 July 2018|date=2015-01-07}}&lt;/ref&gt;

===Injection===
In a study conducted from 1990 through 1995, [[University of New Mexico]] psychiatrist [[Rick Strassman]] found that some volunteers injected with high doses of DMT reported experiences with perceived [[Extraterrestrial life in culture|alien]] entities. Usually, the reported entities were experienced as the inhabitants of a perceived independent reality that the subjects reported visiting while under the influence of DMT.&lt;ref name=&quot;strassman&quot; /&gt;

===Oral ingestion===
{{see also|Ayahuasca}}
{{see also|Pharmahuasca}}
[[File:Aya-preparation.jpg|thumb|Ayahuasca preparation]]
DMT is broken down by the enzyme [[monoamine oxidase]] through a process called [[deamination]], and is quickly inactivated orally unless combined with a [[monoamine oxidase inhibitor]] (MAOI).&lt;ref name=&quot;pmid6587171&quot; /&gt; The traditional South American beverage [[ayahuasca]], or yage, is derived by boiling the [[Banisteriopsis caapi|ayahuasca vine]] (''Banisteriopsis caapi'') with leaves of one or more plants containing DMT, such as ''[[Psychotria viridis]]'', ''[[Psychotria carthagenensis]]'', or ''[[Diplopterys cabrerana]]''.&lt;ref name=&quot;pmid6587171&quot; /&gt; The Ayahuasca vine contains [[harmala alkaloids]],&lt;ref name=&quot;pmid9924842&quot;&gt;{{cite journal |last1=Callaway |first1=James C. |last2=Grob |first2=Charles S. |title=Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions |journal=Journal of Psychoactive Drugs |volume=30 |issue=4 |pages=367–9 |year=1998 |pmid=9924842 |issn=0279-1072 |doi=10.1080/02791072.1998.10399712 |url=http://www.mimosahostilis.com/files/Ayahuasca%20and%20SSRI%20Interactions.pdf |access-date=2012-04-10 |archive-url=https://web.archive.org/web/20120201144245/http://www.mimosahostilis.com/files/Ayahuasca%20and%20SSRI%20Interactions.pdf |archive-date=2012-02-01 |url-status=dead |df= }}&lt;/ref&gt; highly active reversible inihibitors of monoamine oxidase A ([[Reversible inhibitor of monoamine oxidase A|RIMA]]s),&lt;ref name=&quot;BergströmWesterberg1997&quot;&gt;{{cite journal|last1=Bergström|first1=Mats|last2=Westerberg|first2=Göran|last3=Långström|first3=Bengt|title=&lt;sup&gt;11&lt;/sup&gt;C-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies|journal=Nuclear Medicine and Biology|volume=24|issue=4|year=1997|pages=287–293|issn=0969-8051|doi=10.1016/S0969-8051(97)00013-9|pmid=9257326}}&lt;/ref&gt; rendering the DMT orally active by protecting it from [[deamination]].&lt;ref name=&quot;pmid6587171&quot; /&gt; A variety of different recipes are used to make the brew depending on the purpose of the ayahuasca session,&lt;ref name=&quot;Andritzky1989&quot;&gt;{{cite journal|last1=Andritzky|first1=Walter|title=Sociopsychotherapeutic Functions of Ayahuasca Healing in Amazonia|journal=Journal of Psychoactive Drugs|volume=21|issue=1|year=1989|pages=77–89|issn=0279-1072|pmid=2656954|doi=10.1080/02791072.1989.10472145|accessdate=10 April 2012|url=http://www.lila.info/document_view.phtml?document_id=8|archiveurl=https://web.archive.org/web/20080226052014/http://www.lila.info/document_view.phtml?document_id=8|archivedate=26 February 2008|url-status=dead}}&lt;/ref&gt; or local availability of ingredients. Two common sources of DMT in the western US are [[reed canary grass]] (''[[Phalaris arundinacea]]'') and [[Harding grass]] (''[[Phalaris aquatica]]''). These invasive grasses contain low levels of DMT and other alkaloids but also contain [[gramine]], which is toxic and difficult to separate. In addition, [[Mimosa tenuiflora|Jurema]] (''[[Mimosa tenuiflora]]'') shows evidence of DMT content: the pink layer in the inner rootbark of this small tree contains a high concentration of ''N,N''-DMT.{{citation needed|date=December 2014}}

Taken orally with an [[Reversible inhibitor of monoamine oxidase A|RIMA]], DMT produces a long lasting (over 3 hour), slow, deep metaphysical experience similar to that of [[psilocybin mushrooms]], but more intense.&lt;ref name=Peru&gt;{{cite web |url=http://www.kirasalak.com/Peru.html |title=Hell and back |last=Salak |first=Kira |publisher=National Geographic Adventure }}&lt;/ref&gt; [[Reversible inhibitor of monoamine oxidase A|RIMA]]s should be used with caution as they can have fatal interactions with some prescription drugs such as SSRI antidepressants, and some over-the-counter drugs known as sympathomimetics such as Ephedrine or certain cough medicines and even some herbal remedies .&lt;ref name=&quot;pmid9924842&quot; /&gt;

== History ==
DMT has been used in South America since pre-Columbian times.&lt;ref&gt;{{Cite journal|last=Capriles|first=José M.|last2=Moore|first2=Christine|last3=Albarracin-Jordan|first3=Juan|last4=Miller|first4=Melanie J.|date=2019-05-01|title=Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America|journal=Proceedings of the National Academy of Sciences|language=en|pages=11207–11212|doi=10.1073/pnas.1902174116|issn=0027-8424|pmid=31061128|pmc=6561276|volume=116|issue=23}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|url=https://news.berkeley.edu/2019/05/06/ayahuasca-sacred-bundle/|title=Ayahuasca fixings found in 1,000-year-old Andean sacred bundle|last=Anwar|first=Yasmin|last2=May 6|first2=Media Relations{{!}}|date=2019-05-06|website=Berkeley News|language=en-US|access-date=2019-05-21|last3=2019May 16|last4=2019}}&lt;/ref&gt;

DMT was first synthesized in 1931 by chemist Richard Helmuth Fredrick Manske (born 1901 in Berlin, Germany – 1977).&lt;ref name=&quot;Manske R.H.F. 1931 592–600&quot;&gt;{{cite journal|year=1931|title=A synthesis of the methyltryptamines and some derivatives|url=http://rparticle.web-p.cisti.nrc.ca/rparticle/AbstractTemplateServlet?calyLang=eng&amp;journal=cjr&amp;volume=5&amp;year=&amp;issue=5&amp;msno=cjr31-097|journal=Canadian Journal of Research|volume=5|issue=5|pages=592–600|doi=10.1139/cjr31-097|author=Manske R.H.F.|bibcode=1931CJRes...5..592M}}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt;&lt;ref name=&quot;bdmxab&quot;&gt;{{cite journal|date=November 1977|title=DMT: the fifteen minute trip|url=http://jeremybigwood.net/JBsPUBS/DMT/|journal=Head|volume=2|issue=4|pages=56–61|author1=Bigwood J.|author2=Ott J.|accessdate=2010-11-28|archiveurl=https://web.archive.org/web/20060127003553/http://jeremybigwood.net/JBsPUBS/DMT/|archivedate=2006-01-27}}&lt;/ref&gt; In general, its discovery as a natural product is credited to Brazilian chemist and [[Microbiology|microbiologist]] Oswaldo Gonçalves de Lima (1908–1989) who, in 1946, isolated an alkaloid he named ''nigerina'' (nigerine) from the root bark of ''jurema preta'', that is, ''[[Mimosa tenuiflora]]''.&lt;ref name=&quot;bdmxab&quot; /&gt;&lt;ref name=&quot;strassman&quot; /&gt;&lt;ref name=&quot;ott1996&quot;&gt;{{cite book |title=Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History |last=Ott |first=Jonathan |authorlink=Jonathan Ott |edition=2nd, densified |year=1996 |publisher=Natural Products |location=Kennewick, WA |isbn=978-0-9614234-9-0}}&lt;/ref&gt; However, in a careful review of the case [[Jonathan Ott]] shows that the [[empirical formula]] for nigerine determined by Gonçalves de Lima, which notably contains an atom of oxygen, can match only a partial, &quot;impure&quot; or &quot;contaminated&quot; form of DMT.&lt;ref name=&quot;ott1998&quot;&gt;{{cite book |last1=Ott |first1=Jonathan |authorlink1=Jonathan Ott |editor1-first=C. |editor1-last=Müller-Ebeling |title=Special: Psychoactivity |series=Yearbook for Ethnomedicine and the Study of Consciousness |volume=6/7 (1997/1998) |year=1998 |publisher=VWB |location=Berlin |isbn=978-3-86135-033-0 |pages= |chapter=Pharmahuasca, anahuasca and vinho da jurema: human pharmacology of oral DMT plus harmine |chapterurl=https://www.erowid.org/references/texts/show/7105docid6446}}&lt;/ref&gt; It was only in 1959, when Gonçalves de Lima provided American chemists a sample of ''Mimosa tenuiflora'' roots, that DMT was unequivocally identified in this plant material.&lt;ref name=&quot;ott1998&quot; /&gt;&lt;ref&gt;{{cite journal|author1=Pachter I.J. |author2=Zacharias D.E. |author3=Ribeiro O. |title=Indole alkaloids of ''Acer saccharinum'' (the silver maple), ''Dictyoloma incanescens'', ''Piptadenia colubrina'', and ''Mimosa hostilis'' |journal=Journal of Organic Chemistry |date=September 1959 |volume=24 |issue=9 |pages=1285–87 |doi=10.1021/jo01091a032}}&lt;/ref&gt; Less ambiguous is the case of isolation and formal identification of DMT in 1955 in seeds and pods of ''[[Anadenanthera peregrina]]'' by a team of American chemists led by Evan Horning (1916–1993).&lt;ref name=&quot;ott1998&quot; /&gt;&lt;ref&gt;{{cite journal |author1=Fish M.S. |author2=Johnson N.M. |author3=Horning E.C. |date=November 1955 |title=Piptadenia alkaloids. Indole bases of ''P. peregrina'' (L.) Benth. and related species |journal=Journal of the American Chemical Society |volume=72 |issue=22 |pages=5892–95 |url= |doi=10.1021/ja01627a034}}&lt;/ref&gt; Since 1955, DMT has been [[#Endogenous DMT|found in a host of organisms]]: in at least fifty plant species belonging to ten [[Family (biology)|families]],&lt;ref name=&quot;ott1994&quot;&gt;{{cite book|title=Ayahuasca Analogues: Pangæan Entheogens|last=Ott|first=Jonathan|publisher=Natural Products|year=1994|isbn=978-0-9614234-5-2|edition=1st|location=[[Kennewick, WA]], USA|pages=81–3|oclc=32895480|authorlink=Jonathan Ott}}&lt;/ref&gt; and in at least four animal species, including one [[gorgonian]]&lt;ref name=&quot;ReferenceA&quot;&gt;{{cite journal|year=1978|title=Chemistry of Mediterranean gorgonians: simple indole derivatives from ''Paramuricea chamaeleon''|journal=Comparative Biochemistry and Physiology C|volume=61|issue=2|pages=361–2|doi=10.1016/0306-4492(78)90070-9|author1=Cimino G.|author2=De Stefano S.}}&lt;/ref&gt; and three mammalian species.

In terms of a scientific understanding, the hallucinogenic properties of DMT were not uncovered until 1956 by Hungarian chemist and psychiatrist [[Stephen Szára|Stephen Szara]]. In his paper published the same year titled 'Dimethyltryptamine: its metabolism in man' he references the plant ''[[Mimosa hostilis]]'' in which he injected the extract into his own muscle.&lt;ref&gt;{{Cite journal|last=Szara|first=S.|date=1956-11-15|title=Dimethyltryptamin: its metabolism in man; the relation to its psychotic effect to the serotonin metabolism|journal=Experientia|volume=12|issue=11|pages=441–442|issn=0014-4754|pmid=13384414|doi=10.1007/bf02157378}}&lt;/ref&gt; This is considered to be the converging link between the chemical structure DMT to its cultural consumption as a psychoactive and religious sacrament.&lt;ref&gt;{{cite journal | last1 = McKenna | first1 = D. J. | last2 = Callaway | first2 = J. C. | last3 = Grob | first3 = C. S. | year = 1998 | title = The scientific investigation of Ayahuasca: a review of past and current research | url = | journal = The Heffter Review of Psychedelic Research | volume = 1 | issue = 65–77| pages = 195–223 }}&lt;/ref&gt;

Another historical milestone is the discovery of DMT in plants frequently used by Amazonian natives as additive to the vine ''[[Banisteriopsis caapi]]'' to make [[ayahuasca]] decoctions. In 1957, American chemists Francis Hochstein and Anita Paradies identified DMT in an &quot;aqueous extract&quot; of leaves of a plant they named ''Prestonia amazonicum'' (''sic'') and described as &quot;commonly mixed&quot; with ''B. caapi''.&lt;ref&gt;{{cite journal |author1=Hochstein F.A. |author2=Paradies A.M. |year=1957 |title=Alkaloids of ''Banisteria caapi'' and ''Prestonia amazonicum'' |journal=Journal of the American Chemical Society |volume=79 |issue=21 |pages=5735–36 |doi=10.1021/ja01578a041 }}&lt;/ref&gt; The lack of a proper botanical identification of ''[[Prestonia amazonica]]'' in this study led American [[ethnobotany|ethnobotanist]] [[Richard Evans Schultes]] (1915–2001) and other scientists to raise serious doubts about the claimed plant identity.&lt;ref&gt;{{cite journal |author1=Schultes R.E. |author2=Raffauf R.F. |year=1960 |title=''Prestonia'': An Amazon narcotic or not? |journal=Botanical Museum Leaflets, Harvard University |volume=19 |issue=5 |pages=109–122 |issn=0006-8098 |url=https://www.biodiversitylibrary.org/item/31906#page/126/mode/1up |accessdate= }}&lt;/ref&gt;&lt;ref name=&quot;pmid14337385&quot;&gt;{{cite journal |author=Poisson J. |title=Note sur le &quot;Natem&quot;, boisson toxique péruvienne et ses alcaloïdes |trans-title=Note on &quot;Natem&quot;, a toxic Peruvian beverage, and its alkaloids |language=French |journal=Annales Pharmaceutiques Françaises |volume=23 |issue= |pages=241–4 |date=April 1965 |pmid=14337385 |issn=0003-4509}}&lt;/ref&gt; The mistake likely led the writer [[William S. Burroughs|William Burroughs]] to regard the DMT he experimented with in Tangier in 1961 as &quot;Prestonia&quot;.&lt;ref&gt;{{Cite book|title=Mystery School in Hyperspace: A Cultural History of DMT|last=St John|first=Graham|publisher=North Atlantic Books / Evolver|year=2015|isbn=978-1583947326|location=Berkeley, CA.|pages=29}}&lt;/ref&gt; Better evidence was produced in 1965 by French pharmacologist Jacques Poisson, who isolated DMT as a sole alkaloid from leaves, provided and used by [[Aguaruna people|Agaruna]] Indians, identified as having come from the vine ''[[Diplopterys cabrerana]]'' (then known as ''Banisteriopsis rusbyana'').&lt;ref name=&quot;pmid14337385&quot; /&gt; Published in 1970, the first identification of DMT in the plant ''[[Psychotria viridis]]'',&lt;ref name=&quot;ott1996&quot; /&gt; another common additive of ayahuasca, was made by a team of American researchers led by pharmacologist Ara der Marderosian.&lt;ref&gt;{{cite journal |author1=Der Marderosian A.H. |author2=Kensinger K.M. |author3=Chao J.-M. |author4=Goldstein F.J. |year=1970 |title=The use and hallucinatory principles of a psychoactive beverage of the Cashinahua tribe (Amazon basin) |journal=Drug Dependence |volume=5 |issue= |pages=7–14 |issn=0070-7368 |oclc=1566975}}&lt;/ref&gt; Not only did they detect DMT in leaves of ''P. viridis'' obtained from [[Kaxinawá]] [[indigenous people]], but they also were the first to identify it in a sample of an ayahuasca decoction, prepared by the same indigenous people.&lt;ref name=&quot;ott1996&quot; /&gt;

==Legal status==

=== International law ===
{{International legal status for entheogens}}

===By country and continent===

====Asia====
[[Israel]] – DMT is an illegal substance; production, trade and possession are prosecuted as crimes.&lt;ref name=&quot;judge&quot;&gt;{{cite news|url=http://www.ynetnews.com/articles/0,7340,L-4414356,00.html|title=Judge's son arrested for importing 2kg of hallucinogenic drug|first=Eli|last=Senyor|date=2013-08-06|accessdate=2017-08-11|quote=Son of [[Central District (Israel)|central district]] judge arrested for allegedly importing DMT – LSD like drug – from [[Netherlands|Holland]]. [...] The suspect denies the allegations against him and claims he did not know the substance was on the list of illegal drugs.|work=[[Ynetnews]]|publisher=[[Yediot Ahronot]]|location=[[Tel Aviv]]}}&lt;/ref&gt;

====Europe====
* [[France]] – DMT, along with most of its plant sources, is classified as a ''stupéfiant'' ([[narcotic]]).
* [[Germany]] – DMT is prohibited as a class I drug.&lt;ref&gt;{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage I (zu § 1 Abs. 1) (nicht verkehrsfähige Betäubungsmittel)|website=gesetze-im-internet.de}}&lt;/ref&gt;
*[[Republic of Ireland]] – DMT is an illegal Schedule 1 drug under the [[Misuse of Drugs Act (Ireland)|Misuse of Drugs Acts]].&lt;ref&gt;{{cite web|url=https://www.irishexaminer.com/ireland/man-fined-for-having-drug-used-in-amazon-458558.html|title=Man fined for having drug used in Amazon|last1=Friday|last2=September 08|last3=2017|date=8 September 2017|website=www.irishexaminer.com}}&lt;/ref&gt; An attempt in 2014 by a member of the [[Santo Daime]] church to gain a religious exemption to import the drug failed.&lt;ref&gt;{{cite web|url=https://www.independent.ie/irish-news/courts/sect-leader-spared-jail-for-importing-hallucinogenic-drug-for-religious-sacrament-36377897.html|title=Sect leader spared jail for importing hallucinogenic drug for religious 'sacrament'|website=Independent.ie}}&lt;/ref&gt;
* [[Latvia]] — DMT is prohibited as a Schedule I drug.&lt;ref&gt;{{cite web|url=https://likumi.lv/ta/id/121086-noteikumi-par-latvija-kontrolejamajam-narkotiskajam-vielam-psihotropajam-vielam-un-prekursoriem#piel1|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|accessdate=13 February 2019|location=|website=likumi.lv}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=https://likumi.lv/ta/en/en/id/121086|title=Regulations Regarding Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia|accessdate=13 February 2019|location=|website=likumi.lv}}&lt;/ref&gt;
* [[Netherlands]] – The drug is banned as it is classified as a List 1 Drug per the [[Opium Law]]. Production, trade and possession of DMT are prohibited.
* [[Russia]] – Classified as a Schedule I narcotic, including its derivatives (see [[sumatriptan]] and [[zolmitriptan]]).&lt;ref&gt;{{cite web|url=http://base.garant.ru/12112176/|title=Постановление Правительства РФ от 30.06.1998 N 681 &quot;Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации&quot; (с изменениями и дополнениями)|website=base.garant.ru}}&lt;/ref&gt;
* [[Serbia]] –  DMT, along with stereoisomers and salts is classified as List 4 (Psychotropic substances) substance according to Act on Control of Psychoactive Substances.
* [[Sweden]] - DMT is considered a Schedule 1 drug. The Swedish supreme court concluded in 2018 that possession of processed plant material containing a significant amount of DMT is illegal. However, possession of unprocessed such plant material was ruled legal.&lt;ref&gt;{{cite web|url=https://lakemedelsverket.se/upload/lvfs/LVFS_2011-10.pdf|title=Läkemedelsverkets författningssamling}}&lt;/ref&gt;&lt;ref&gt;http://www.hogstadomstolen.se/Domstolar/hogstadomstolen/Avgoranden/2018/2018-12-13%20B%201605-18%20Dom.pdf{{Dead link|date=September 2019 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt; 
* [[United Kingdom]] – DMT is classified as a [[Misuse of Drugs Act 1971|Class A drug]].
* [[Belgium]] - DMT cannot be possessed, sold, purchased or imported. Usage is not specifically prohibited, but since usage implies possession one could be prosecuted that way.&lt;ref&gt;{{Cite web | url=https://www.druglijn.be/drugs-abc/lsd-en-tripmiddelen/wetgeving | title=Wetgeving rond LSD en tripmiddelen &amp;#124; Druglijn.be}}&lt;/ref&gt;

====North America====
* [[Canada]] – DMT is classified as a [[Controlled Drugs and Substances Act|Schedule III]] drug under the Controlled Drugs and Substances Act.

In 2017 the [[Santo Daime]] Church Céu do Montréal received religious exemption to use [[Ayahuasca]] as a sacrament in their rituals.&lt;ref&gt;{{Cite web|url=https://chacruna.net/how-ayahuasca-church-received-religious-exemption-canada/|title=How Our Santo Daime Church Received Religious Exemption to Use Ayahuasca in Canada|last=Rochester|first=Rev Dr Jessica|date=2017-07-17|website=Chacruna|language=en-US|access-date=2019-05-01}}&lt;/ref&gt;

*[[United States]] – DMT is classified in the United States as a [[List of Schedule I drugs (US)|Schedule I]] drug under the [[Controlled Substances Act|Controlled Substances Act of 1970]].

In December 2004, the [[Supreme Court of the United States|Supreme Court]] lifted a stay, thereby allowing the [[Brazil]]-based [[União do Vegetal]] (UDV) church to use a decoction containing DMT in their Christmas services that year. This decoction is a tea made from boiled leaves and vines, known as [[hoasca]] within the UDV, and [[ayahuasca]] in different cultures. In ''[[Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal]]'', the Supreme Court heard arguments on November 1, 2005, and unanimously ruled in February 2006 that the U.S. federal government must allow the UDV to import and consume the tea for religious ceremonies under the 1993 [[Religious Freedom Restoration Act]].

In September 2008, the three [[Santo Daime]] churches filed suit in federal court to gain legal status to import DMT-containing [[ayahuasca]] tea. The case, ''[[Santo Daime|Church of the Holy Light of the Queen]] v. Mukasey'',&lt;ref&gt;{{cite web|url=http://csp.org/society/docs/SantoDaimeAshland20090318.pdf|title=Church of the Holy Light of the Queen v. Mukasey|access-date=2018-12-05|archive-url=https://web.archive.org/web/20111003151720/http://csp.org/society/docs/SantoDaimeAshland20090318.pdf|archive-date=2011-10-03|url-status=dead|df=}}&lt;/ref&gt; presided over by Judge [[Owen M. Panner]], was ruled in favor of the Santo Daime church. As of March 21, 2009, a federal judge says members of the church in [[Ashland, Oregon|Ashland]] can import, distribute and brew ayahuasca. U.S. District Judge [[Owen Panner]] issued a permanent injunction barring the government from prohibiting or penalizing the sacramental use of &quot;Daime tea&quot;. Panner's order said activities of The Church of the Holy Light of the Queen are legal and protected under [[freedom of religion]]. His order prohibits the federal government from interfering with and prosecuting church members who follow a list of regulations set out in his order.&lt;ref&gt;{{cite court|litigants=Church of the Holy Light of the Queen v. Mukasey|court=D. Ore. |reporter= |vol= |opinion= |pinpoint= |date=2009|url=http://www.bialabate.net/wp-content/uploads/2009/04/161-31909-permanent-injunction.pdf|quote=permanently enjoins Defendants from prohibiting or penalizing the sacramental use of Daime tea by Plaintiffs during Plaintiffs' religious ceremonies}}&lt;/ref&gt;

====Oceania====
* [[New Zealand]] – DMT is classified as a Class A drug under the [[Misuse of Drugs Act 1975]].&lt;ref&gt;{{cite news|url=http://www.stuff.co.nz/marlborough-express/news/5025678/Rare-drug-bound-for-Blenheim|title=Rare drug bound for Blenheim|last=Berry|first=Michael|date=19 May 2011|publisher=[[Fairfax New Zealand]]|location=[[Blenheim, New Zealand]]|authorlink2=New Zealand Press Association|author2=NZPA|newspaper=Malborough Express|accessdate=23 May 2012}}&lt;/ref&gt;&lt;ref name=&quot;NZMoDA&quot;&gt;{{cite web|url=http://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436576.html|title=Schedule 1: Class A controlled drugs|date=1 May 2012|publisher=[[Parliamentary Counsel Office (New Zealand)|Parliamentary Counsel Office/Te Tari Tohutohu Pāremata]]|location=[[Wellington]], N.Z.|ref=NZMoDA|website=Misuse of Drugs Act 1975|accessdate=23 May 2012}}&lt;/ref&gt;

* [[Australia]] – DMT is listed as a Schedule 9 prohibited substance in [[Australia]] under the [[Standard for the Uniform Scheduling of Medicines and Poisons|Poisons Standard]] (October 2015).&lt;ref name=&quot;Poisons Standard&quot;&gt;Poisons Standard October 2015 [https://www.comlaw.gov.au/Details/F2015L01534 comlaw.gov.au]&lt;/ref&gt; A schedule 9 drug is outlined in the [[Poisons Act 1964]] as &quot;Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO.&quot;&lt;ref&gt;Poisons Act 1964 [http://www.slp.wa.gov.au/pco/prod/FileStore.nsf/Documents/MRDocument:26063P/$FILE/Poisons%20Act%201964%20-%20%5B09-f0-04%5D.pdf?OpenElement slp.wa.gov.au] {{webarchive|url=https://web.archive.org/web/20151222191725/http://www.slp.wa.gov.au/pco/prod/FileStore.nsf/Documents/MRDocument%3A26063P/%24FILE/Poisons%20Act%201964%20-%20%5B09-f0-04%5D.pdf?OpenElement |date=2015-12-22 }}&lt;/ref&gt;

Under the [[Misuse of Drugs act 1981]] 6.0 g of DMT is considered enough to determine a court of trial and 2.0 g is considered intent to sell and supply.&lt;ref&gt;Misuse of Drugs Act 1981 (2015) [http://www.slp.wa.gov.au/pco/prod/FileStore.nsf/Documents/MRDocument:28280P/$FILE/Misuse%20Of%20Drugs%20Act%201981%20-%20%5B06-e0-00%5D.pdf?OpenElement slp.wa.gov.au] {{webarchive|url=https://web.archive.org/web/20151222180141/http://www.slp.wa.gov.au/pco/prod/FileStore.nsf/Documents/MRDocument%3A28280P/%24FILE/Misuse%20Of%20Drugs%20Act%201981%20-%20%5B06-e0-00%5D.pdf?OpenElement |date=2015-12-22 }}&lt;/ref&gt;

Between 2011 and 2012, the [[Australian Federal Government]] was considering changes to the [[Criminal law of Australia|Australian Criminal Code]] that would classify any plants containing any amount of DMT as &quot;controlled plants&quot;.&lt;ref&gt;{{cite web|url=http://www.ag.gov.au/www/agd/agd.nsf/Page/Consultationsreformsandreviews_ConsultationonimplementationofmodeldrugschedulesforCommonwealthseriousdrugoffences|title=Consultation on implementation of model drug schedules for Commonwealth serious drug offenses|date=24 June 2010|publisher=[[Attorney-General's Department (Australia)|Australian Government, Attorney-General's Department]]|url-status=dead|archiveurl=https://web.archive.org/web/20111107074102/http://www.ag.gov.au/www/agd/agd.nsf/Page/Consultationsreformsandreviews_ConsultationonimplementationofmodeldrugschedulesforCommonwealthseriousdrugoffences|archivedate=7 November 2011|df=}}&lt;/ref&gt; DMT itself was already controlled under current laws. The proposed changes included other similar blanket bans for other substances, such as a ban on any and all plants containing Mescaline or Ephedrine. The proposal was not pursued after political embarrassment on realisation that this would make the official [[List of Australian floral emblems|Floral Emblem of Australia]], [[Acacia pycnantha]] (Golden Wattle), illegal. The Therapeutic Goods Administration and federal authority had considered a motion to ban the same, but this was withdrawn in May 2012 (as DMT may still hold potential entheogenic value to native and/or religious people).&lt;ref&gt;{{cite journal |date=August 2012 |title=AUSSIE DMT BAN |url=http://connection.ebscohost.com/c/articles/79564875/aussie-dmt-ban |journal=American Herb Association Quarterly Newsletter |volume=27 |issue=3 |pages=14}}&lt;/ref&gt;

==Chemistry==
[[File:D-Tryp.jpg|thumb|DMT crystals]]DMT is commonly handled and stored as a [[fumaric acid|fumarate]],&lt;ref name=&quot;erowid.org&quot;&gt;{{cite web|url=https://www.erowid.org/library/books_online/tihkal/tihkal06.shtml|title=Erowid Online Books : &quot;TIHKAL&quot; - #6 DMT|website=www.erowid.org}}&lt;/ref&gt; as other DMT acid salts are extremely [[Hygroscopy|hygroscopic]] and will not readily crystallize. Its [[Freebase (chemistry)|freebase]] form, although less stable than DMT fumarate, is favored by recreational users choosing to vaporize the chemical as it has a lower boiling point.&lt;ref name=&quot;erowid.org&quot; /&gt;

===Biosynthesis===
[[Image:DMT biosynthetic pathway.png|thumb|left|Biosynthetic pathway for ''N'',''N''-dimethyltryptamine]]
Dimethyltryptamine is an [[indole alkaloid]] derived from the [[shikimate]] pathway. Its [[biosynthesis]] is relatively simple and summarized in the adjacent picture. In plants, the parent amino acid [[L-tryptophan]] is produced endogenously where in animals [[L-tryptophan]] is an [[essential amino acid]] coming from diet. No matter the source of [[L-tryptophan]], the biosynthesis begins with its [[decarboxylation]] by an [[aromatic amino acid decarboxylase]] (AADC) [[enzyme]] (step 1). The resulting decarboxylated tryptophan [[Analog (chemistry)|analog]] is [[tryptamine]]. Tryptamine then undergoes a [[transmethylation]] (step 2): the enzyme [[tryptamine-N-methyltransferase|indolethylamine-N-methyltransferase]] (INMT) [[Catalysis|catalyzes]] the transfer of a [[methyl group]] from [[Cofactor (biochemistry)|cofactor]] [[S-adenosyl-methionine]] (SAM), via [[nucleophilic]] attack, to tryptamine. This reaction transforms SAM into [[S-adenosylhomocysteine]] (SAH), and gives the intermediate product [[N-methyltryptamine|''N''-methyltryptamine]] (NMT).&lt;ref name=&quot;pmid13685339&quot;&gt;{{cite journal |author=Axelrod J. |title=Enzymatic formation of psychotomimetic metabolites from normally occurring compounds |journal=Science |volume=134 |issue= 3475|page=343 |date=August 1961 |pmid=13685339 |doi=10.1126/science.134.3475.343 |url=|bibcode=1961Sci...134..343A }}&lt;/ref&gt;&lt;ref name=&quot;pmid779022&quot;&gt;{{cite journal |author1=Rosengarten H. |author2=Friedhoff A.J. |title=A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances |journal=Schizophrenia Bulletin |volume=2 |issue=1 |pages=90–105 |year=1976 |pmid=779022 |doi=10.1093/schbul/2.1.90 |url=http://schizophreniabulletin.oxfordjournals.org/content/2/1/90.full.pdf }}&lt;/ref&gt; NMT is in turn transmethylated by the same process (step 3) to form the end product ''N'',''N''-dimethyltryptamine. Tryptamine transmethylation is regulated by two products of the reaction: SAH,&lt;ref name=&quot;pmid6792104&quot;&gt;{{Cite book |author1=Barker S.A. |author2=Monti J.A. |author3=Christian S.T. |title=''N, N''-dimethyltryptamine: an endogenous hallucinogen |volume=22 |pages=83–110 |year=1981 |pmid=6792104 |doi=10.1016/S0074-7742(08)60291-3 |series=International Review of Neurobiology |isbn=978-0-12-366822-6}}&lt;/ref&gt;&lt;ref name=&quot;pmid4756800&quot;&gt;{{cite journal |author1=Lin R.L. |author2=Narasimhachari N. |author3=Himwich H.E. |title=Inhibition of indolethylamine-N-methyltransferase by S-adenosylhomocysteine |journal=Biochemical and Biophysical Research Communications |volume=54 |issue=2 |pages=751–9 |date=September 1973 |pmid=4756800 |doi=10.1016/0006-291X(73)91487-3 |url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid9852119&quot;&gt;{{cite journal |author1=Thompson M.A. |author2=Weinshilboum R.M. |title=Rabbit lung indolethylamine ''N''-methyltransferase. cDNA and gene cloning and characterization |journal=Journal of Biological Chemistry |volume=273 |issue=51 |pages=34502–10 |date=December 1998 |pmid=9852119 |doi=10.1074/jbc.273.51.34502 }}&lt;/ref&gt; and DMT&lt;ref name=&quot;pmid6792104&quot; /&gt;&lt;ref name=&quot;pmid9852119&quot; /&gt; were shown ''ex vivo'' to be among the most potent inhibitors of rabbit INMT activity.

This transmethylation mechanism has been repeatedly and consistently proven by [[Isotope labeling|radiolabeling]] of SAM methyl group with [[carbon-14]] (&lt;sup&gt;14&lt;/sup&gt;C-CH&lt;sub&gt;3&lt;/sub&gt;)SAM.&lt;ref name=&quot;pmid13685339&quot; /&gt;&lt;ref name=&quot;pmid6792104&quot; /&gt;&lt;ref name=&quot;pmid9852119&quot; /&gt;&lt;ref name=&quot;pmid14361&quot;&gt;{{cite journal |author1=Mandel L.R. |author2=Prasad R. |author3=Lopez-Ramos B. |author4=Walker R.W. |title=The biosynthesis of dimethyltryptamine in vivo |journal=Research Communications in Chemical Pathology and Pharmacology |volume=16 |issue=1 |pages=47–58 |date=January 1977 |pmid=14361}}&lt;/ref&gt;&lt;ref name=&quot;pmid10552930&quot;&gt;{{cite journal |author1=Thompson M.A. |author2=Moon E. |author3=Kim U.J. |author4=Xu J. |author5=Siciliano M.J. |author6=Weinshilboum R.M. |title=Human indolethylamine ''N''-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization |journal=Genomics |volume=61 |issue=3 |pages=285–97 |date=November 1999 |pmid=10552930 |doi=10.1006/geno.1999.5960 |url=http://crfdl.org:1111/xmlui/bitstream/handle/123456789/307/Thompson99humanINMT.pdf?sequence=1 |format=PDF }}{{dead link|date=March 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt;

===Laboratory synthesis===
DMT can be synthesized through several possible pathways from different starting materials. The two most commonly encountered synthetic routes are through the reaction of [[indole]] with [[oxalyl chloride]] followed by reaction with [[dimethylamine]] and reduction of the carbonyl functionalities with [[lithium aluminum hydride]] to form DMT.&lt;ref&gt;{{cite web|url=https://erowid.org/library/books_online/tihkal/tihkal06.shtml|title=Erowid Online Books : &quot;TIHKAL&quot; - #6 DMT|website=erowid.org}}&lt;/ref&gt; The second commonly encountered route is through the n,n-dimethylation of tryptamine using formaldehyde followed by reduction with sodium cyanoborohydride or sodium triacetoxyborohydride. Sodium borohydride is not used as it reduces the formaldehyde to methanol before it is able to react with the primary amine of tryptamine.

===Clandestine manufacture===
[[File:Dmt1234.jpg|right|thumb|DMT during various stages of purification]]
In a clandestine setting, DMT is not typically synthesized due to the lack of availability of the starting materials, namely [[tryptamine]] and [[oxalyl chloride]]. Instead, it is more often extracted from plant sources using a non-polar hydrocarbon solvent such as [[naphtha]] or [[heptane]], and a [[Base (chemistry)|base]] such as [[sodium hydroxide]].

Alternatively, an [[acid-base extraction]] is sometimes used instead.

A variety of plants contain DMT at sufficient levels for being viable sources,{{citation needed|date=July 2019}} but specific plants such as ''[[Mimosa tenuiflora]]'' and ''[[Acacia confusa]]'' are most often used.

The chemicals involved in the extraction are commonly available. The plant material may be illegal to procure in some countries. The end product (DMT) is illegal in most countries.

====Evidence in mammals====
Published in ''[[Science (journal)|Science]]'' in 1961, [[Julius Axelrod]] found an ''N''-[[methyltransferase]] enzyme capable of mediating biotransformation of tryptamine into DMT in a rabbit's lung.&lt;ref name=&quot;pmid13685339&quot; /&gt; This finding initiated a still ongoing scientific interest in endogenous DMT production in humans and other mammals.&lt;ref name=&quot;pmid779022&quot; /&gt;&lt;ref name=&quot;pmid16095048&quot;&gt;{{cite journal |author1=Kärkkäinen J. |author2=Forsström T. |author3=Tornaeus J. |author4=Wähälä K. |author5=Kiuru P. |author6=Honkanen A. |author7=Stenman U.-H. |author8=Turpeinen U. |author9=Hesso A. |date=April 2005 |title=Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues |journal=Scandinavian Journal of Clinical and Laboratory Investigation |volume=65 |issue=3 |pages=189–199 |quote= |doi=10.1080/00365510510013604 |pmid=16095048}}&lt;/ref&gt; From then on, two major complementary lines of evidence have been investigated: localization and further characterization of the ''N''-methyltransferase enzyme, and [[Analytical chemistry|analytical studies]]&amp;nbsp;looking for endogenously produced DMT in body fluids and tissues.&lt;ref name=&quot;pmid779022&quot; /&gt;

In 2013 researchers first reported DMT in the [[pineal gland]] [[microdialysis|microdialysate]] of rodents.&lt;ref name=&quot;pmid23881860&quot;&gt;{{cite journal |vauthors=Barker SA, Borjigin J, Lomnicka I, Strassman R |title=LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate |journal=Biomed. Chromatogr. |date=Jul 2013 |volume= 27|issue= 12|pages= 1690–1700|pmid=23881860 |doi=10.1002/bmc.2981|url=https://deepblue.lib.umich.edu/bitstream/2027.42/101767/1/bmc2981.pdf|hdl=2027.42/101767 }}&lt;/ref&gt;

A study published in 2014 reported the biosynthesis of N,N-dimethyltryptamine (DMT) in the human melanoma cell line SK-Mel-147 including details on its metabolism by peroxidases.&lt;ref name=&quot;pmid24508833&quot;&gt;{{cite journal |vauthors=Gomes MM, Coimbra JB, Clara RO, Dörr FA, Moreno AC, Chagas JR, Tufik S, ((Pinto E Jr)), Catalani LH, Campa A |title=Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases |journal=Biochemical Pharmacology |date=2014 |volume=88 |issue=3 |pages=393–401 |pmid=24508833 |doi=10.1016/j.bcp.2014.01.035}}&lt;/ref&gt;

In a 2014 paper a group first demonstrated the immunomodulatory potential of DMT and [[5-MeO-DMT]] through the [[Sigma-1 receptor]] of human immune cells. This immunomodulatory activity may contribute to significant anti-inflammatory effects and tissue regeneration.&lt;ref name=&quot;pmid25171370&quot;&gt;{{cite journal |vauthors=Szabo A, Kovacs A, Frecska E, Rajnavolgyi E |title=Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells |journal=PLoS ONE |date=29 Aug 2014 |volume=9 |issue=8 |pages=e106533 |pmid=25171370 |doi=10.1371/journal.pone.0106533 |pmc=4149582|bibcode=2014PLoSO...9j6533S }}&lt;/ref&gt;

=====Endogenous DMT=====
The first claimed detection of mammalian [[endogenous]] DMT was published in June 1965: German researchers F. Franzen and H. Gross report to have evidenced and quantified DMT, along with its [[structural analog]] bufotenin (5-HO-DMT), in human blood and urine.&lt;ref name=&quot;pmid5839067&quot;&gt;{{cite journal |author1=Franzen F. |author2=Gross H. |title=Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine |journal=Nature |volume=206 |issue=988 |page=1052 |date=June 1965 |pmid=5839067 |doi=10.1038/2061052a0 |url=|quote=After the elaboration of sufficiently selective and quantitative procedures, which are discussed elsewhere, we were able to study the occurrence of tryptamine, ''N'',''N''-dimethyltryptamine, ''N'',''N''-dimethyl-5-hydroxytryptamine and 5-hydroxytryptamine in normal human blood and urine. (...) In 11 of 37 probands ''N'',''N''-dimethyltryptamine was demonstrated in blood (...). In the urine 42·95 ± 8·6 μg of dimethyltryptamine/24 h were excreted.|bibcode=1965Natur.206.1052F }}&lt;/ref&gt; In an article published four months later, the method used in their study was strongly criticized, and the credibility of their results challenged.&lt;ref name=&quot;pmid5860629&quot;&gt;{{cite journal |author=Siegel M. |title=A sensitive method for the detection of N,N-dimethylserotonin (bufotenin) in urine; failure to demonstrate its presence in the urine of schizophrenic and normal subjects |journal=Journal of Psychiatric Research |volume=3 |issue=3 |pages=205–11 |date=October 1965 |pmid=5860629 |doi=10.1016/0022-3956(65)90030-0 |url=}}&lt;/ref&gt;

Few of the analytical methods used prior to 2001 to measure levels of endogenously formed DMT had enough sensitivity and selectivity to produce reliable results.&lt;ref name=&quot;pmid11232854&quot;&gt;{{cite journal |author1=Barker S.A. |author2=Littlefield-Chabaud M.A. |author3=David C. |title=Distribution of the hallucinogens ''N'',''N''-dimethyltryptamine and 5-methoxy-''N'',''N''-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method |journal=Journal of Chromatography B |volume=751 |issue=1 |pages=37–47 |date=February 2001 |pmid=11232854 |doi=10.1016/S0378-4347(00)00442-4 |url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid11763413&quot;&gt;{{cite journal |author1=Forsström T. |author2=Tuominen J. |author3=Karkkäinen J. |title=Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS |journal=Scandinavian Journal of Clinical and Laboratory Investigation |volume=61 |issue=7 |pages=547–56 |year=2001 |pmid=11763413 |doi=10.1080/003655101753218319 |url=}}&lt;/ref&gt; [[Gas chromatography]], preferably coupled to [[mass spectrometry]] ([[GC-MS]]), is considered a minimum requirement.&lt;ref name=&quot;pmid11763413&quot; /&gt; A study published in 2005&lt;ref name=&quot;pmid16095048&quot; /&gt; implements the most sensitive and selective method ever used to measure endogenous DMT:&lt;ref name=&quot;pmid20523750&quot;&gt;{{cite journal |author1=Shen H.W. |author2=Jiang X.L. |author3=Yu A.M. |title=Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study |journal=Bioanalysis |volume=1 |issue=1 |pages=87–95 |date=April 2009 |pmid=20523750 |pmc=2879651 |doi=10.4155/bio.09.7 }}&lt;/ref&gt; [[High-performance liquid chromatography|liquid chromatography]]-[[tandem mass spectrometry]] with [[electrospray ionization]] (LC-ESI-MS/MS) allows for reaching limits of detection (LODs) 12 to 200 fold lower than those attained by the best methods employed in the 1970s. The data summarized in the table below are from studies conforming to the abovementioned requirements (abbreviations used: CSF = [[cerebrospinal fluid]]; LOD = [[limit of detection]]; n = number of samples; ng/L and ng/kg = nanograms (10&lt;sup&gt;−9&lt;/sup&gt; g) per litre, and nanograms per kilogram, respectively):

{| class=&quot;wikitable&quot; border=&quot;1&quot; cellpadding=&quot;2&quot; cellspacing=&quot;1&quot; style=&quot;margin: 1em auto 1em auto; width:70%;&quot;
|+ align=&quot;bottom&quot; | '''DMT''' in body fluids and tissues ''(NB: units have been harmonized)''
! style=&quot;background:azure; vertical-align:middle; text-align:center; width:30px;&quot; | Species
! style=&quot;background:azure; vertical-align:middle; text-align:center; width:60px;&quot; | Sample
! style=&quot;background:azure; vertical-align:middle; text-align:center; width:400px;&quot; | Results
|-
! rowspan=&quot;8&quot; style=&quot;background:oldLace; vertical-align:top; text-align:center; width:30px;&quot; | Human
| style=&quot;vertical-align:middle; background:oldLace; width:60px;&quot; | [[Blood serum]]
| style=&quot;vertical-align:middle; background:oldLace; width:400px;&quot; | &amp;lt; LOD (n = 66)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|-
| style=&quot;vertical-align:middle; background:oldLace; width:60px;&quot; | [[Blood plasma]]
| style=&quot;vertical-align:middle; background:oldLace; width:400px;&quot; | &amp;lt; LOD (n = 71)&lt;ref name=&quot;pmid16095048&quot; /&gt; &amp;nbsp;♦&amp;nbsp; &amp;lt; LOD (n = 38); 1,000 &amp; 10,600&amp;nbsp;ng/L (n = 2)&lt;ref name=&quot;pmid4517484&quot;&gt;{{cite journal |author1=Wyatt R.J. |author2=Mandel L.R. |author3=Ahn H.S. |author4=Walker R.W. |author5=Vanden Heuvel W.J. |title=Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients |journal=Psychopharmacologia |volume=31 |issue=3 |pages=265–70 |date=July 1973 |pmid=4517484 |doi=10.1007/BF00422516 }}&lt;/ref&gt;
|-
| style=&quot;vertical-align:middle; background:oldLace; width:60px;&quot; | Whole blood
| style=&quot;vertical-align:middle; background:oldLace; width:400px;&quot; | &amp;lt; LOD (n = 20); 50–790&amp;nbsp;ng/L (n = 20)&lt;ref name=&quot;pmid803203&quot;&gt;{{cite journal |author1=Angrist B. |author2=Gershon S. |author3=Sathananthan G. |author4=Walker R.W. |author5=Lopez-Ramos B. |author6=Mandel L.R. |author7=Vandenheuvel W.J. |title=Dimethyltryptamine levels in blood of schizophrenic patients and control subjects |journal=Psychopharmacology |volume=47 |issue=1 |pages=29–32 |date=May 1976 |pmid=803203 |doi=10.1007/BF00428697 }}&lt;/ref&gt;
|-
| style=&quot;vertical-align:middle; background:oldLace; width:60px;&quot; | Urine
| style=&quot;vertical-align:middle; background:oldLace; width:400px;&quot; | &amp;lt; 100&amp;nbsp;ng/L (n = 9)&lt;ref name=&quot;pmid16095048&quot; /&gt; &amp;nbsp;♦&amp;nbsp; &amp;lt; LOD (n = 60); 160–540&amp;nbsp;ng/L (n = 5)&lt;ref name=&quot;pmid11763413&quot; /&gt; &amp;nbsp;♦&amp;nbsp; Detected in n = 10 by GC-MS&lt;ref name=&quot;pmid271509&quot;&gt;{{cite journal |author1=Oon M.C. |author2=Rodnight R. |title=A gas chromatographic procedure for determining ''N'', ''N''-dimethyltryptamine and ''N''-monomethyltryptamine in urine using a nitrogen detector |journal=Biochemical Medicine |volume=18 |issue=3 |pages=410–9 |date=December 1977 |pmid=271509 |doi=10.1016/0006-2944(77)90077-1 |url=}}&lt;/ref&gt;
|- style=&quot;vertical-align:middle; background:oldLace;&quot;
| style=&quot;width:60px;&quot; | Feces
| style=&quot;width:400px;&quot; | &amp;lt; 50&amp;nbsp;ng/kg (n&amp;nbsp;= 12); 130&amp;nbsp;ng/kg (n = 1)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|- style=&quot;vertical-align:middle; background:oldLace;&quot;
| style=&quot;width:60px;&quot; | Kidney
| style=&quot;width:400px;&quot; | 15&amp;nbsp;ng/kg (n = 1)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|- style=&quot;vertical-align:middle; background:oldLace;&quot;
| style=&quot;width:60px;&quot; | Lung
| style=&quot;width:400px;&quot; | 14&amp;nbsp;ng/kg (n = 1)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|-
| style=&quot;vertical-align:middle; background:oldLace; width:60px;&quot; | [[Lumbar puncture|Lumbar]] CSF
| style=&quot;vertical-align:middle; background:oldLace; width:400px;&quot; | 100,370&amp;nbsp;ng/L (n = 1); 2,330–7,210&amp;nbsp;ng/L (n = 3); 350 &amp; 850&amp;nbsp;ng/L (n = 2)&lt;ref name=&quot;pmid289421&quot;&gt;{{cite journal |author1=Smythies J.R. |author2=Morin R.D. |author3=Brown G.B. |title=Identification of dimethyltryptamine and ''O''-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry |journal=Biological Psychiatry |volume=14 |issue=3 |pages=549–56 |date=June 1979 |pmid=289421 |doi= |url=}}&lt;/ref&gt;
|-
! rowspan=&quot;4&quot; style=&quot;background:#dcdcdc; vertical-align:top; text-align:center; width:30px;&quot; | Rat
| style=&quot;vertical-align:middle; background:#dcdcdc; width:60px;&quot; | Kidney
| style=&quot;vertical-align:middle; background:#dcdcdc; width:400px;&quot; | 12 &amp;amp;16&amp;nbsp;ng/kg (n = 2)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|- style=&quot;vertical-align:middle; background:#dcdcdc;&quot;
| style=&quot;width:60px;&quot; | Lung
| style=&quot;width:400px;&quot; | 22 &amp; 12&amp;nbsp;ng/kg (n = 2)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|- style=&quot;vertical-align:middle; background:#dcdcdc;&quot;
| style=&quot;width:60px;&quot; | Liver
| style=&quot;width:400px;&quot; | 6 &amp; 10&amp;nbsp;ng/kg (n = 2)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|-
| style=&quot;vertical-align:middle; background:#dcdcdc; width:60px;&quot; | Brain
| style=&quot;vertical-align:middle; background:#dcdcdc; width:400px;&quot; | 10 &amp;amp;15&amp;nbsp;ng/kg (n = 2)&lt;ref name=&quot;pmid16095048&quot; /&gt; &amp;nbsp;♦ &amp;nbsp;Measured in [[Synaptic vesicle|synaptic vesicular]] [[Fractionation|fraction]]&lt;ref name=&quot;pmid20877&quot;&gt;{{cite journal |author1=Christian S.T. |author2=Harrison R. |author3=Quayle E. |author4=Pagel J. |author5=Monti J. |title=The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent |journal=Biochemical Medicine |volume=18 |issue=2 |pages=164–83 |date=October 1977 |pmid=20877 |doi=10.1016/0006-2944(77)90088-6 |url=}}&lt;/ref&gt;
|-
! style=&quot;vertical-align:middle; background:honeyDew; width:30px;&quot; | Rabbit
| style=&quot;vertical-align:middle; background:honeyDew; width:60px;&quot; | Liver
| style=&quot;vertical-align:middle; background:honeyDew; width:400px;&quot; | &amp;lt; 10&amp;nbsp;ng/kg (n = 1)&lt;ref name=&quot;pmid16095048&quot; /&gt;
|}

A 2013 study found DMT in [[Microdialysis|microdialysate]] obtained from a rat's pineal gland, providing evidence of endogenous DMT in the mammalian brain.&lt;ref name=&quot;pmid23881860&quot; /&gt; In 2019 experiments showed that the rat brain is capable of synthesizing and releasing DMT. These results raise the possibility that this phenomenon may occur similarly in human brains.&lt;ref&gt;{{Cite journal|last=Borjigin|first=Jimo|last2=Wang|first2=Michael M.|last3=Strassman|first3=Rick J.|last4=Steven A. Barker|last5=Sheler|first5=Ben|last6=Huff|first6=Sean|last7=Liu|first7=Tiecheng|last8=Dean|first8=Jon G.|date=2019-06-27|title=Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain|journal=Scientific Reports|language=en|volume=9|issue=1|pages=9333|doi=10.1038/s41598-019-45812-w|pmid=31249368|pmc=6597727|issn=2045-2322|bibcode=2019NatSR...9.9333D}}&lt;/ref&gt;

===Detection in body fluids===
DMT may be measured in blood, plasma or urine using chromatographic techniques as a diagnostic tool in clinical poisoning situations or to aid in the medicolegal investigation of suspicious deaths. In general, blood or plasma DMT levels in recreational users of the drug are in the 10–30 μg/L range during the first several hours post-ingestion.{{Citation needed|reason=Such precise values range needs one or more reliable sources|date=January 2012}} Less than 0.1% of an oral dose is eliminated unchanged in the 24-hour urine of humans.&lt;ref&gt;{{cite journal | author1 = Callaway JC |author2=Raymon LP |author3=Hearn WL | journal = J. Anal. Toxicol. | volume = 20 | pages = 492–497 | year = 1996 | pmid = 8889686 | title = Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca | issue = 6 | doi = 10.1093/jat/20.6.492 }}&lt;/ref&gt;&lt;ref&gt;R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 9th edition, Biomedical Publications, Seal Beach, CA, 2011, pp. 525–526.&lt;/ref&gt;{{Clarify|date=March 2014|reason=unclear language, eliminated unchanged?}}

====INMT====

Before techniques of [[molecular biology]] were used to localize [[indolethylamine N-methyltransferase|indolethylamine ''N''-methyltransferase]] (INMT),&lt;ref name=&quot;pmid9852119&quot; /&gt;&lt;ref name=&quot;pmid10552930&quot; /&gt; characterization and localization went on a par: samples of the biological material where INMT is hypothesized to be active are subject to [[enzyme assay]]. Those enzyme assays are performed either with a radiolabeled methyl donor like (&lt;sup&gt;14&lt;/sup&gt;C-CH&lt;sub&gt;3&lt;/sub&gt;)SAM to which known amounts of unlabeled substrates like tryptamine are added&lt;ref name=&quot;pmid779022&quot; /&gt; or with addition of a radiolabeled substrate like (&lt;sup&gt;14&lt;/sup&gt;C)NMT to demonstrate [[in vivo]] formation.&lt;ref name=&quot;pmid6792104&quot; /&gt;&lt;ref name=&quot;pmid14361&quot; /&gt; As qualitative determination of the radioactively tagged product of the enzymatic reaction is sufficient to characterize INMT existence and activity (or lack of), analytical methods used in INMT assays are not required to be as sensitive as those needed to directly detect and quantify the minute amounts of endogenously formed DMT (see DMT subsection below). The essentially qualitative method [[thin layer chromatography]] (TLC) was thus used in a vast majority of studies.&lt;ref name=&quot;pmid779022&quot; /&gt; Also, robust evidence that INMT can catalyze transmethylation of tryptamine into NMT and DMT could be provided with [[Isotopic dilution|reverse isotope dilution analysis]] coupled to [[mass spectrometry]] for rabbit&lt;ref name=&quot;pmid5150167&quot;&gt;{{cite journal|date=March 1971|title=Purification and substrate specificity of indoleamine-''N''-methyl transferase|url=|journal=Biochemical Pharmacology|volume=20|issue=3|pages=712–6|doi=10.1016/0006-2952(71)90158-4|pmid=5150167|author1=Mandel L.R.|author2=Rosenzweig S.|author3=Kuehl F.A.}}&lt;/ref&gt;&lt;ref name=&quot;pmid1056183&quot;&gt;{{cite journal|date=June 1975|title=''N''-methylation of 1-methyltryptamines by indolethylamine ''N''-methyltransferase|url=|journal=Biochemical Pharmacology|volume=24|issue=11–12|pages=1239–40|doi=10.1016/0006-2952(75)90071-4|pmid=1056183|author1=Lin R.-L.|author2=Narasimhachari N.}}&lt;/ref&gt; and human&lt;ref name=&quot;pmid5034200&quot;&gt;{{cite journal|date=April 1972|title=Indoleamine-''N''-methyl transferase in human lung|url=|journal=Biochemical Pharmacology|volume=21|issue=8|pages=1197–200|doi=10.1016/0006-2952(72)90113-X|pmid=5034200|author1=Mandel L.R.|author2=Ahn H.S.|author3=VandenHeuvel W.J.}}&lt;/ref&gt; lung during the early 1970s.

Selectivity rather than sensitivity proved to be an Achilles' heel for some TLC methods with the discovery in 1974–1975 that incubating rat blood cells or brain tissue with (&lt;sup&gt;14&lt;/sup&gt;C-CH&lt;sub&gt;3&lt;/sub&gt;)SAM and NMT as substrate mostly yields tetrahydro-β-carboline derivatives,&lt;ref name=&quot;pmid779022&quot; /&gt;&lt;ref name=&quot;pmid6792104&quot; /&gt;&lt;ref name=&quot;pmid1067427&quot;&gt;{{cite journal|year=1976|title=Possible source of error in studies of enzymatic formation of dimethyltryptamine|url=|journal=Journal of Psychiatric Research|volume=13|issue=1|pages=23–30|doi=10.1016/0022-3956(76)90006-6|pmid=1067427|author1=Rosengarten H.|author2=Meller E.|author3=Friedhoff A.J.}}&lt;/ref&gt; and negligible amounts of DMT in brain tissue.&lt;ref name=&quot;pmid779022&quot; /&gt; It is indeed simultaneously realized that the TLC methods used thus far in almost all published studies on INMT and DMT biosynthesis are incapable to resolve DMT from those tetrahydro-β-carbolines.&lt;ref name=&quot;pmid779022&quot; /&gt; These findings are a blow for all previous claims of evidence of INMT activity and DMT biosynthesis in avian&lt;ref name=&quot;pmid5793241&quot;&gt;{{cite journal|date=August 1969|title=Indole(ethyl)amine N-methyltransferase in the brain|url=|journal=Science|volume=165|issue=3892|pages=492–3|doi=10.1126/science.165.3892.492|pmid=5793241|author1=Morgan M.|author2=Mandell A.J.|bibcode=1969Sci...165..492M}}&lt;/ref&gt; and mammalian brain,&lt;ref name=&quot;pmid5279043&quot;&gt;{{cite journal|date=March 1971|title=Indole(ethyl)amine N-methyltransferase in human brain|url=|journal=Nature New Biology|volume=230|issue=11|pages=85–7|doi=10.1038/newbio230085a0|pmid=5279043|author1=Mandell A.J.|author2=Morgan M.}}&lt;/ref&gt;&lt;ref name=&quot;pmid4703789&quot;&gt;{{cite journal|date=March 1973|title=The distribution and properties of the nonspecific ''N''-methyltransferase in brain|url=|journal=Journal of Neurochemistry|volume=20|issue=3|pages=743–52|doi=10.1111/j.1471-4159.1973.tb00035.x|pmid=4703789|author1=Saavedra J.M.|author2=Coyle J.T.|author3=Axelrod J.}}&lt;/ref&gt; including [[in vivo]],&lt;ref name=&quot;pmid5059565&quot;&gt;{{cite journal|date=March 1972|title=Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro|url=http://crfdl.org:1111/xmlui/bitstream/handle/123456789/392/1733285.pdf?sequence=1|format=PDF|journal=Science|volume=175|issue=4028|pages=1365–6|doi=10.1126/science.175.4028.1365|pmid=5059565|author1=Saavedra J.M.|author2=Axelrod J.|bibcode=1972Sci...175.1365S}}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt;&lt;ref name=&quot;pmid4725358&quot;&gt;{{cite journal|date=July 1973|title=Distribution and metabolism of tryptamine in rat brain|url=|journal=Canadian Journal of Biochemistry|volume=51|issue=7|pages=1104–12|doi=10.1139/o73-144|pmid=4725358|author1=Wu P.H.|author2=Boulton A.A.}}&lt;/ref&gt; as they all relied upon use of the problematic TLC methods:&lt;ref name=&quot;pmid779022&quot; /&gt; their validity is doubted in replication studies that make use of improved TLC methods, and fail to evidence DMT-producing INMT activity in rat and human brain tissues.&lt;ref name=&quot;pmid963555&quot;&gt;{{cite journal|date=September 1976|title=Tryptamine-N-methyltransferase activity in brain tissue: a re-examination|journal=Brain Research|volume=114|issue=2|pages=359–64|doi=10.1016/0006-8993(76)90680-6|pmid=963555|author1=Boarder M.R.|author2=Rodnight R.}}&lt;/ref&gt;&lt;ref name=&quot;pmid823298&quot;&gt;{{cite journal|date=September 1976|title=Enzymatic ''N''-methylation of indoleamines by mammalian brain: fact or artefact?|url=|journal=Journal of Neurochemistry|volume=27|issue=3|pages=701–5|doi=10.1111/j.1471-4159.1976.tb10397.x|pmid=823298|author1=Gomes U.R.|author2=Neethling A.C.|author3=Shanley B.C.}}&lt;/ref&gt; Published in 1978, the last study attempting to evidence [[in vivo]] INMT activity and DMT production in brain (rat) with TLC methods finds biotransformation of radiolabeled tryptamine into DMT to be real but &quot;insignificant&quot;.&lt;ref name=&quot;pmid279646&quot;&gt;{{cite journal|date=October 1978|title=Lack of enhancement of dimethyltryptamine formation in rat brain and rabbit lung in vivo by methionine or ''S''-adenosylmethionine|url=|journal=Journal of Neurochemistry|volume=31|issue=4|pages=1015–20|doi=10.1111/j.1471-4159.1978.tb00141.x|pmid=279646|author1=Stramentinoli G.|author2=Baldessarini R.J.}}&lt;/ref&gt; Capability of the method used in this latter study to resolve DMT from tetrahydro-β-carbolines is questioned later.&lt;ref name=&quot;pmid6792104&quot; /&gt;&lt;br /&gt;
To localize INMT, a qualitative leap is accomplished with use of modern techniques of [[molecular biology]], and of [[immunohistochemistry]]. In humans, a gene encoding INMT is determined to be located on [[Chromosome 7 (human)|chromosome 7]].&lt;ref name=&quot;pmid10552930&quot; /&gt; [[Northern blot|Northern blot analyses]] reveal INMT [[messenger RNA]] (mRNA) to be highly expressed in rabbit lung,&lt;ref name=&quot;pmid9852119&quot; /&gt; and in human [[thyroid]], [[adrenal gland]], and lung.&lt;ref name=&quot;pmid10552930&quot; /&gt;&lt;ref name=&quot;UniProtO95050&quot;&gt;{{cite web|url=https://www.uniprot.org/uniprot/O95050|title=INMT - Indolethylamine N-methyltransferase - Homo sapiens (Human) - INMT gene &amp; protein|website=www.uniprot.org}}&lt;/ref&gt; Intermediate levels of expression are found in human heart, skeletal muscle, trachea, stomach, small intestine, pancreas, testis, prostate, placenta, [[lymph node]], and spinal cord.&lt;ref name=&quot;pmid10552930&quot; /&gt;&lt;ref name=&quot;UniProtO95050&quot; /&gt; Low to very low levels of expression are noted in rabbit brain,&lt;ref name=&quot;pmid10552930&quot; /&gt; and human [[thymus]], liver, [[spleen]], kidney, colon, ovary, and [[bone marrow]].&lt;ref name=&quot;pmid10552930&quot; /&gt;&lt;ref name=&quot;UniProtO95050&quot; /&gt; INMT mRNA expression is absent in human peripheral blood [[White blood cell|leukocytes]], whole brain, and in tissue from 7 specific brain regions (thalamus, subthalamic nucleus, caudate nucleus, hippocampus, amygdala, substantia nigra, and corpus callosum).&lt;ref name=&quot;pmid10552930&quot; /&gt;&lt;ref name=&quot;UniProtO95050&quot; /&gt; [[Immunohistochemistry]] showed INMT to be present in large amounts in [[Goblet cell|glandular epithelial cells]] of small and large intestines. In 2011, immunohistochemistry revealed the presence of INMT in primate nervous tissue including retina, spinal cord motor neurons, and pineal gland.&lt;ref name=&quot;Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E. 2011 840.19&quot;&gt;{{cite journal|date=2011|title=Indolethylamine N-methyltransferase expression in primate nervous tissue|url=http://www.neurophys.wisc.edu/~cozzi/Indolethylamine%20N-methyltransferase%20expression%20in%20primate%20nervous%20tissue.pdf|journal=Society for Neuroscience Abstracts|volume=37|pages=840.19|author1=Cozzi N.V.|author2=Mavlyutov T.A.|author3=Thompson M.A.|author4=Ruoho A.E.|access-date=2012-09-20|archive-url=https://web.archive.org/web/20120913184820/http://www.neurophys.wisc.edu/~cozzi/Indolethylamine%20N-methyltransferase%20expression%20in%20primate%20nervous%20tissue.pdf|archive-date=2012-09-13|url-status=dead|df=}}&lt;/ref&gt;

==Pharmacology==

===Pharmacokinetics===
DMT peak level concentrations (''C''&lt;sub&gt;max&lt;/sub&gt;) measured in whole blood after intramuscular (IM) injection (0.7&amp;nbsp;mg/kg, n = 11)&lt;ref name=&quot;pmid4607811&quot;&gt;{{cite journal |author1=Kaplan J. |author2=Mandel L.R. |author3=Stillman R. |author4=Walker R.W. |author5=VandenHeuvel W.J. |author6=Gillin J.C. |author7=Wyatt R.J. |title=Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects |journal=Psychopharmacologia |volume=38 |issue=3 |pages=239–45 |year=1974 |pmid=4607811 |doi=10.1007/BF00421376 }}&lt;/ref&gt; and in plasma following intravenous (IV) administration (0.4&amp;nbsp;mg/kg, n = 10)&lt;ref name=&quot;pmid8297216&quot; /&gt; of fully psychedelic doses are in the range of ≈14 to 154 μg/L and 32 to 204 μg/L, respectively.
The corresponding [[molar concentration]]s of DMT are therefore in the range of 0.074–0.818 μM in whole blood and 0.170–1.08 μM in plasma. However, several studies have described active transport and accumulation of DMT into rat and dog brain following peripheral administration.&lt;ref name=&quot;pmid6812592&quot;&gt;{{cite journal |author1=Barker S.A. |author2=Beaton J.M. |author3=Christian S.T. |author4=Monti J.A. |author5=Morris P.E. |title=Comparison of the brain levels of N,N-dimethyltryptamine and α, α, β, β-tetradeutero-N-N-dimethyltryptamine following intraperitoneal injection. The in vivo kinetic isotope effect |journal=[[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] |volume=31 |issue=15 |pages=2513–6 |date=August 1982 |pmid=6812592 |doi=10.1016/0006-2952(82)90062-4 |url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid41604&quot;&gt;{{cite journal |author1=Sangiah S. |author2=Gomez M.V. |author3=Domino E.F. |title=Accumulation of ''N,N''-dimethyltryptamine in rat brain cortical slices |journal=Biological Psychiatry |volume=14 |issue=6 |pages=925–36 |date=December 1979 |pmid=41604}}&lt;/ref&gt;&lt;ref name=&quot;pmid3472526&quot;&gt;{{cite journal |author1=Sitaram B.R. |author2=Lockett L. |author3=Talomsin R. |author4=Blackman G.L. |author5=McLeod W.R. |title=''In vivo'' metabolism of 5-methoxy-''N,N''-dimethyltryptamine and ''N,N''-dimethyltryptamine in the rat |journal=Biochemical Pharmacology |volume=36 |issue=9 |pages=1509–12 |date=May 1987 |pmid=3472526 |doi=10.1016/0006-2952(87)90118-3}}&lt;/ref&gt;&lt;ref name=&quot;pmid3866749&quot;&gt;{{cite journal |author1=Takahashi T. |author2=Takahashi K. |author3=Ido T. |author4=Yanai K. |author5=Iwata R. |author6=Ishiwata K. |author7=Nozoe S. |title= [&lt;sup&gt;11&lt;/sup&gt;C]-labeling of indolealkylamine alkaloids and the comparative study of their tissue distributions |journal=International Journal of Applied Radiation and Isotopes |volume=36 |issue=12 |pages=965–9 |date=December 1985 |pmid=3866749 |doi=10.1016/0020-708X(85)90257-1}}&lt;/ref&gt;&lt;ref name=&quot;pmid3489620&quot;&gt;{{cite journal |author1=Yanai K. |author2=Ido T. |author3=Ishiwata K. |author4=Hatazawa J |author5=Takahashi T. |author6=Iwata R. |author7=Matsuzawa T. |title=''In vivo'' kinetics and displacement study of a carbon-11-labeled hallucinogen, ''N,N''-(&lt;sup&gt;11&lt;/sup&gt;C)dimethyltryptamine |journal=European Journal of Nuclear Medicine |volume=12 |issue=3 |pages=141–6 |year=1986 |pmid=3489620 |doi=10.1007/BF00276707 }}&lt;/ref&gt;
Similar active transport, and accumulation processes likely occur in human brain and may concentrate DMT in brain by several-fold or more (relatively to blood), resulting in local concentrations in the micromolar or higher range. Such concentrations would be commensurate with serotonin brain tissue concentrations, which have been consistently determined to be in the 1.5-4 μM range.&lt;ref name=&quot;pmid20723248&quot;&gt;{{cite journal |author1=Best, J. |author2=Nijhout, H. F. |author3=Reed, M. |title=Serotonin synthesis, release and reuptake in terminals: a mathematical model |journal=Theoretical Biology &amp; Medical Modelling |volume=7 |issue=1 |page=34 |year=2010 |pmid=20723248 |pmc=2942809 |doi=10.1186/1742-4682-7-34}}&lt;/ref&gt;&lt;ref name=&quot;pmid16146432&quot;&gt;{{cite journal |author1=Merrill, M. A. |author2=Clough, R. W. |author3=Jobe, P. C. |author4=Browning R. A. |title=Brainstem seizure severity regulates forebrain seizure expression in the audiogenic kindling model |journal=Epilepsia |volume=46 |issue=9 |pages=1380–8 |date=September 2005 |pmid=16146432 |doi=10.1111/j.1528-1167.2005.39404.x |url=http://assets0.pubget.com/pdf/16146432.pdf |archive-url=https://web.archive.org/web/20181031214030/http://assets0.pubget.com/pdf/16146432.pdf |url-status=dead |archive-date=2018-10-31 }}&lt;/ref&gt;

Closely coextending with peak psychedelic effects, mean time to reach peak concentrations (''T''&lt;sub&gt;max&lt;/sub&gt;) was determined to be 10–15 minutes in whole blood after IM injection,&lt;ref name=&quot;pmid4607811&quot; /&gt; and 2 minutes in plasma after IV administration.&lt;ref name=&quot;pmid8297216&quot; /&gt; When taken orally mixed in an [[ayahuasca]] decoction, and in [[Freeze-drying|freeze-dried]] ayahuasca [[Capsule (pharmacy)#Two-piece gel encapsulation|gel caps]], DMT ''T''&lt;sub&gt;max&lt;/sub&gt; is considerably delayed: 107.59 ± 32.5 minutes,&lt;ref name=&quot;pmid10404423&quot;&gt;{{cite journal |author1=Callaway J.C. |author2=McKenna D.J. |author3=Grob C.S. |author4=Brito G.S. |author5=Raymon L.P. |author6=Poland R.E. |author7=Andrade E.N. |title=Pharmacokinetics of ''Hoasca'' alkaloids in healthy humans |journal=Journal of Ethnopharmacology |volume=65 |issue=3 |pages=243–56 |date=June 1999 |pmid=10404423 |doi=10.1016/S0378-8741(98)00168-8 |url=http://wiki.dmt-nexus.com/w/images/2/26/Pharmacokinetics_of_hoasca_in_healthy_humans.pdf |display-authors=etal }}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt; and 90–120 minutes,&lt;ref name=&quot;pmid12660312&quot;&gt;{{cite journal |author1=Riba J. |author2=Valle M. |author3=Urbano G. |author4=Yritia M. |author5=Morte A. |author6=Barbanoj M.J. |title=Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics |journal=Journal of Pharmacology and Experimental Therapeutics |volume=306 |issue=1 |pages=73–83 |date=July 2003 |pmid=12660312 |doi=10.1124/jpet.103.049882 |url=https://semanticscholar.org/paper/c4959f19d1e160a9fb97676fd43c660c3df896f4 }}&lt;/ref&gt; respectively.
The pharmacokinetics for vaporizing DMT have not been studied or reported.

===Pharmacodynamics===
DMT binds non-[[binding selectivity|selectively]] with [[affinity (pharmacology)|affinities]] &lt; 0.6 μM to the following [[serotonin receptor]]s: [[5-HT1A receptor|5-HT&lt;sub&gt;1A&lt;/sub&gt;]],&lt;ref name=&quot;pmid19881490&quot;&gt;{{cite journal |author1=Keiser M. J. |author2=Setola V. |author3=Irwin J. J. |author4=Laggner C. |author5=Abbas A. I. |author6=Hufeisen S. J. |author7=Jensen N. H. |title=Predicting new molecular targets for known drugs |journal=Nature |volume=462 |issue=7270 |pages=175–81 |date=November 2009 |pmid=19881490 |pmc=2784146 |doi=10.1038/nature08506 |display-authors=etal|bibcode=2009Natur.462..175K }}&lt;/ref&gt;&lt;ref name=&quot;pmid1828347&quot;&gt;{{cite journal |author1=Deliganis A. V. |author2=Pierce P. A. |author3=Peroutka S. J. |title=Differential interactions of dimethyltryptamine (DMT) with 5-HT&lt;sub&gt;1A&lt;/sub&gt; and 5-HT&lt;sub&gt;2&lt;/sub&gt; receptors |journal=Biochemical Pharmacology |volume=41 |issue=11 |pages=1739–44 |date=June 1991 |pmid=1828347 |doi=10.1016/0006-2952(91)90178-8 |url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid2540505&quot;&gt;{{cite journal |author1=Pierce P. A. |author2=Peroutka S. J. |title=Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex |journal=Psychopharmacology |volume=97 |issue=1 |pages=118–22 |year= 1989 |pmid=2540505 |doi=10.1007/BF00443425 }}&lt;/ref&gt; [[5-HT1B receptor|5-HT&lt;sub&gt;1B&lt;/sub&gt;]],&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot;&gt;{{cite journal |author=Ray T. S. |title= Psychedelics and the human receptorome |journal= PLoS ONE |volume= 5 |issue= 2 |pages= e9019 |year=2010 |pmid= 20126400 |pmc= 2814854 |doi= 10.1371/journal.pone.0009019 |bibcode= 2010PLoSO...5.9019R }}&lt;/ref&gt; [[5-HT1D receptor|5-HT&lt;sub&gt;1D&lt;/sub&gt;]],&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid2540505&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt; [[5-HT2A receptor|5-HT&lt;sub&gt;2A&lt;/sub&gt;]],&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid2540505&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt;&lt;ref name=&quot;pmid9768567&quot;&gt;{{cite journal |author1=Smith R. L. |author2=Canton H. |author3=Barrett R. J. |author4=Sanders-Bush E. |title=Agonist properties of ''N'',''N''-dimethyltryptamine at serotonin 5-HT&lt;sub&gt;2A&lt;/sub&gt; and 5-HT&lt;sub&gt;2C&lt;/sub&gt; receptors |journal=Pharmacology Biochemistry and Behavior |volume=61 |issue=3 |pages=323–30 |date=November 1998 |pmid=9768567 |doi=10.1016/S0091-3057(98)00110-5 |url=http://crfdl.org:1111/xmlui/bitstream/handle/123456789/17/Agonist%20Properties%20of%20N,N-Dimethyltryptaminenext%20term%20at%20Ser.pdf }}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt; [[5-HT2B receptor|5-HT&lt;sub&gt;2B&lt;/sub&gt;]],&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt; [[5-HT2C receptor|5-HT&lt;sub&gt;2C&lt;/sub&gt;]],&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt;&lt;ref name=&quot;pmid9768567&quot; /&gt; [[5-HT6 receptor|5-HT&lt;sub&gt;6&lt;/sub&gt;]],&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt; and [[5-HT7 receptor|5-HT&lt;sub&gt;7&lt;/sub&gt;]].&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt; An [[agonist]] action has been determined at 5-HT&lt;sub&gt;1A&lt;/sub&gt;,&lt;ref name=&quot;pmid1828347&quot; /&gt; 5-HT&lt;sub&gt;2A&lt;/sub&gt; and 5-HT&lt;sub&gt;2C&lt;/sub&gt;.&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt;&lt;ref name=&quot;pmid9768567&quot; /&gt; Its [[intrinsic activity|efficacies]] at other serotonin receptors remain to be determined. Of special interest will be the determination of its efficacy at human 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptor as two ''in vitro'' assays evidenced DMT's high affinity for this receptor: 0.108 μM&lt;ref name=&quot;pmid20126400&quot; /&gt; and 0.184 μM.&lt;ref name=&quot;pmid19881490&quot; /&gt; This may be of importance because chronic or frequent uses of serotonergic drugs showing preferential high affinity and clear agonism at 5-HT&lt;sub&gt;2B&lt;/sub&gt; receptor have been causally linked to [[valvular heart disease]].&lt;ref name=&quot;pmid19505264&quot;&gt;{{cite journal |author1=Rothman R. B. |author2=Baumann M. H. |title=Serotonergic Drugs and Valvular Heart Disease |journal=Expert Opinion on Drug Safety |volume=8 |issue=3 |pages=317–29 |date=May 2009 |pmid=19505264 |pmc=2695569 |doi=10.1517/14740330902931524 }}&lt;/ref&gt;&lt;ref name=&quot;pmid17202450&quot;&gt;{{cite journal |author=Roth B. L. |title=Drugs and valvular heart disease |journal=New England Journal of Medicine |volume=356 |issue=1 |pages=6–9 |date=January 2007 |pmid=17202450 |doi=10.1056/NEJMp068265}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author1=Jonathan D. Urban |author2=William P. Clarke |author3=Mark von Zastrow |author4=David E. Nichols |author5=Brian Kobilka |author6=Harel Weinstein |author7=Jonathan A. Javitch |author8=Bryan L. Roth |author9=Arthur Christopoulos |author10=Patrick M. Sexton |author11=Keith J. Miller |author12=Michael Spedding |author13=Richard B. Mailman |title=Functional Selectivity and Classical Concepts of Quantitative Pharmacology |journal= Journal of Pharmacology and Experimental Therapeutics|volume=320 |issue=1 |pages=1–13 |date=2006-06-27 |doi=10.1124/jpet.106.104463 |pmid=16803859|url=https://cdr.lib.unc.edu/concern/articles/xs55mf307 }}&lt;/ref&gt;

It has also been shown to possess affinity for the [[dopamine]] [[D1 receptor|D&lt;sub&gt;1&lt;/sub&gt;]], [[α1-adrenergic receptor|α&lt;sub&gt;1&lt;/sub&gt;-adrenergic]], [[α2-adrenergic receptor|α&lt;sub&gt;2&lt;/sub&gt;-adrenergic]], [[Imidazoline receptor|imidazoline-1]], and [[sigma-1 receptor|σ&lt;sub&gt;1&lt;/sub&gt;]] [[receptor (biochemistry)|receptors]].&lt;ref name=&quot;pmid2540505&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt;&lt;ref name=&quot;pmid16962229&quot;&gt;{{cite journal |last1=Burchett |first1=Scott A. |last2=Hicks |first2=T. Philip |title=The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain |journal=Progress in Neurobiology |date=August 2006 |volume=79 |issue=5–6 |pages=223–46 |url=http://www.mimosahostilis.com/files/The%20mysterious%20trace%20amines%20%20protean%20neuromodulato.pdf |accessdate=9 May 2012 |doi=10.1016/j.pneurobio.2006.07.003 |pmid=16962229 |issn=0301-0082 |oclc=231983957 |archive-url=https://web.archive.org/web/20120201112618/http://www.mimosahostilis.com/files/The%20mysterious%20trace%20amines%20%20protean%20neuromodulato.pdf |archive-date=1 February 2012 |url-status=dead |df=dmy-all }}&lt;/ref&gt; Converging lines of evidence established activation of the σ&lt;sub&gt;1&lt;/sub&gt; receptor at concentrations of 50–100 μM.&lt;ref name=&quot;pmid19213917&quot;&gt;{{cite journal |author1=Fontanilla D. |author2=Johannessen M. |author3=Hajipour A. R. |author4=Cozzi N. V. |author5=Jackson M. B. |author6=Ruoho A. E. |title=The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator |journal=Science |volume=323 | issue=5916 |pages=934–7 |date=February 2009 |pmid=19213917 |pmc=2947205 |doi=10.1126/science.1166127 |bibcode=2009Sci...323..934F }}&lt;/ref&gt; Its efficacies at the other receptor binding sites are unclear. It has also been shown ''in vitro'' to be a [[substrate (biochemistry)|substrate]] for the cell-surface [[serotonin transporter]] (SERT) and the intracellular [[vesicular monoamine transporter 2]] (VMAT2), inhibiting SERT-mediated serotonin uptake in human platelets at an average concentration of 4.00 ± 0.70 μM and VMAT2-mediated serotonin uptake in vesicles (of [[Fall armyworm|army worm]] Sf9 cells) expressing rat VMAT2 at an average concentration of 93 ± 6.8 μM.&lt;ref name=&quot;pmid19756361&quot;&gt;{{cite journal |author1=Cozzi N. V. |author2=Gopalakrishnan A. |author3=Anderson L. L. |author4=Feih J. T. |author5=Shulgin A. T. |author6=Daley P. F. |author7=Ruoho A. E. |title=Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter |journal=Journal of Neural Transmission |volume=116 |issue=12 |pages=1591–9 |date=December 2009 |pmid=19756361 |doi=10.1007/s00702-009-0308-8 |url=http://www.neurophys.wisc.edu/~cozzi/Hallucinogenic%20tryptamines%20as%20SERT%20and%20VMAT2%20substrates.%20%20Cozzi.%20%20J.%20Neural%20Transm.,%20116,%201591-1599%20(2009).pdf |access-date=2010-11-20 |archive-url=https://web.archive.org/web/20100617172010/http://www.neurophys.wisc.edu/~cozzi/Hallucinogenic%20tryptamines%20as%20SERT%20and%20VMAT2%20substrates.%20%20Cozzi.%20%20J.%20Neural%20Transm.,%20116,%201591-1599%20(2009).pdf |archive-date=2010-06-17 |url-status=dead |df= }}&lt;/ref&gt;

As with other so-called &quot;classical hallucinogens&quot;,&lt;ref name=&quot;nida1994&quot;&gt;{{cite book |last1=Glennon |first1=R. A. |authorlink1= |editor1-first=G. C. |editor1-last=Lin |editor2-first=R. A. |editor2-last=Glennon |title=Hallucinogens: An Update |chapter-url=http://crfdl.org:1111/xmlui/bitstream/handle/123456789/288/hallucinogens%20an%20update.pdf |series=NIDA Research Monograph Series |volume=146 |year=1994 |publisher=U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse |location=Rockville, MD |isbn= |page=4 |chapter=Classical hallucinogens: an introductory overview }}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt; a large part of DMT psychedelic effects can be attributed to a [[functionally selective]] activation of the 5-HT&lt;sub&gt;2A&lt;/sub&gt; receptor.&lt;ref name=&quot;pmid8297216&quot; /&gt;&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid17977517&quot;&gt;{{cite journal |author1=Fantegrossi W. E. |author2=Murnane K. S. |author3=Reissig C. J. |title=The behavioral pharmacology of hallucinogens |journal=Biochemical Pharmacology |volume=75 |issue=1 |pages=17–33 |date=January 2008 |pmid=17977517 |pmc=2247373 |doi=10.1016/j.bcp.2007.07.018 }}&lt;/ref&gt;&lt;ref name=&quot;pmid14761703&quot;&gt;{{cite journal |author= Nichols D. E. |title= Hallucinogens |journal= Pharmacology &amp; Therapeutics |volume=101 |issue=2 |pages=131–81 |date=February 2004 |pmid=14761703 |doi=10.1016/j.pharmthera.2003.11.002 |url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid9875725&quot;&gt;{{cite journal |author1=Vollenweider F. X. |author2=Vollenweider-Scherpenhuyzen M. F. |author3=Bäbler A. |author4=Vogel H. |author5=Hell D. |title= Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action |journal=NeuroReport |volume=9 |issue=17 |pages=3897–902 |date=December 1998 |pmid=9875725 |doi=10.1097/00001756-199812010-00024 |url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid8788488&quot;&gt;{{cite journal |author=Strassman R. J. |title=Human psychopharmacology of N,N-dimethyltryptamine |journal=Behavioural Brain Research |volume=73 |issue=1–2 |pages=121–4 |year=1996 |pmid=8788488 |doi=10.1016/0166-4328(96)00081-2 |url=http://crfdl.org:1111/xmlui/bitstream/handle/123456789/373/Beh_Brain_Res_96.pdf }}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt;&lt;ref name=&quot;pmid6513725&quot;&gt;{{cite journal |author1=Glennon R. A. |author2=Titeler M. |author3=McKenney J. D. |title=Evidence for 5-HT&lt;sub&gt;2&lt;/sub&gt; involvement in the mechanism of action of hallucinogenic agents |journal=Life Sciences |volume=35 |issue=25 |pages=2505–11 |date=December 1984 |pmid=6513725 |doi=10.1016/0024-3205(84)90436-3 |url=}}&lt;/ref&gt; DMT concentrations eliciting 50% of its maximal effect (half maximal effective concentration = [[EC50|EC&lt;sub&gt;50&lt;/sub&gt;]] or K&lt;sub&gt;act&lt;/sub&gt;) at the human 5-HT&lt;sub&gt;2A&lt;/sub&gt; receptor ''in vitro'' are in the 0.118–0.983 μM range.&lt;ref name=&quot;pmid19881490&quot; /&gt;&lt;ref name=&quot;pmid20126400&quot; /&gt;&lt;ref name=&quot;pmid9768567&quot; /&gt;&lt;ref name=&quot;pmid9023266&quot;&gt;{{cite journal |author1=Roth B. L. |author2=Choudhary M. S. |author3=Khan N. |author4=Uluer A. Z. |title=High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine&lt;sub&gt;2A&lt;/sub&gt; receptors: evidence in favor of a modified ternary complex model |journal=Journal of Pharmacology and Experimental Therapeutics |volume=280 |issue=2 |pages=576–83 |date=February 1997 |pmid=9023266 |doi= |url=http://jpet.aspetjournals.org/content/280/2/576.full.pdf }}&lt;/ref&gt; This range of values coincides well with the range of concentrations measured in blood and plasma after administration of a fully psychedelic dose (see [[#Pharmacokinetics|Pharmacokinetics]]).

As DMT has been shown to have slightly better efficacy (EC&lt;sub&gt;50&lt;/sub&gt;) at human serotonin 2C receptor than at the 2A receptor,&lt;ref name=&quot;pmid20126400&quot; /&gt;&lt;ref name=&quot;pmid9768567&quot; /&gt; 5-HT&lt;sub&gt;2C&lt;/sub&gt; is also likely implicated in DMT's overall effects.&lt;ref name=&quot;pmid14761703&quot; /&gt;&lt;ref name=&quot;pmid20165943&quot;&gt;{{cite journal |author1=Canal C. E. |author2=Olaghere da Silva U. B. |author3=Gresch P. J. |author4=Watt E. E. |author5=Sanders-Bush E. |author6=Airey D. C. |title=The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen |journal=Psychopharmacology |volume=209 |issue=2 |pages=163–74 |date=April 2010 |pmid=20165943 |doi=10.1007/s00213-010-1784-0 |pmc=2868321}}&lt;/ref&gt; Other receptors, such as 5-HT&lt;sub&gt;1A&lt;/sub&gt;&lt;ref name=&quot;pmid2540505&quot; /&gt;&lt;ref name=&quot;pmid14761703&quot; /&gt;&lt;ref name=&quot;pmid8788488&quot; /&gt; σ&lt;sub&gt;1&lt;/sub&gt;,&lt;ref name=&quot;pmid19213917&quot; /&gt;&lt;ref name=&quot;pmid19278957&quot;&gt;{{cite journal |author1=Su T. P. |author2=Hayashi T. |author3=Vaupel D. B. |title=When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor |journal=Science Signaling |volume=2 |issue=61 |pages=pe12 |year=2009 |pmid=19278957 |doi=10.1126/scisignal.261pe12 |url=http://crfdl.org:1111/xmlui/bitstream/handle/123456789/3/Su%20et%20alvScience%20Signaling%202009.pdf |pmc=3155724 }}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}&lt;/ref&gt; may also play a role.

In 2009, it was hypothesized that DMT may be an [[endogenous ligand]] for the σ&lt;sub&gt;1&lt;/sub&gt; receptor.&lt;ref name=&quot;pmid19213917&quot; /&gt;&lt;ref name=&quot;pmid19278957&quot; /&gt; The concentration of DMT needed for σ&lt;sub&gt;1&lt;/sub&gt; activation ''in vitro'' (50–100 μM) is similar to the behaviorally active concentration measured in [[mouse brain]] of approximately 106 μM&lt;ref name=&quot;pmid6798607&quot;&gt;{{cite journal |author1=Morinan A. |author2=Collier J. G. |title=Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice |journal=Psychopharmacology |volume=75 |issue=2 |pages=179–83 |year=1981 |pmid=6798607 |doi=10.1007/BF00432184 |url=}}&lt;/ref&gt; This is minimally 4 orders of magnitude higher than the average concentrations measured in rat brain tissue or human plasma under basal conditions (see [[#Endogenous DMT|Endogenous DMT]]), so σ&lt;sub&gt;1&lt;/sub&gt; receptors are likely to be activated only under conditions of high local DMT concentrations. If DMT is stored in synaptic vesicles,&lt;ref name=&quot;pmid19756361&quot; /&gt; such concentrations might occur during vesicular release. To illustrate, while the ''average'' concentration of serotonin in brain tissue is in the 1.5–4 μM range,&lt;ref name=&quot;pmid20723248&quot; /&gt;&lt;ref name=&quot;pmid16146432&quot; /&gt; the concentration of serotonin in synaptic vesicles was measured at 270 mM.&lt;ref name=&quot;pmid11086995&quot;&gt;{{cite journal |author1=Bruns D. |author2=Riedel D. |author3=Klingauf J. |author4=Jahn R. |title=Quantal release of serotonin |journal=Neuron |volume=28 |issue=1 |pages=205–20 |date=October 2000 |pmid=11086995 |doi=10.1016/S0896-6273(00)00097-0 |url=}}&lt;/ref&gt; Following vesicular release, the resulting concentration of serotonin in the synaptic cleft, to which serotonin receptors are exposed, is estimated to be about 300 μM. Thus, while ''in vitro'' receptor binding affinities, efficacies, and average concentrations in tissue or plasma are useful, they are not likely to predict DMT concentrations in the vesicles or at synaptic or intracellular receptors. Under these conditions, notions of receptor selectivity are moot, and it seems probable that most of the receptors identified as targets for DMT (see above) participate in producing its psychedelic effects.

{| class=&quot;wikitable&quot;
|-
! Binding sites
! Binding affinity ''K&lt;sub&gt;i&lt;/sub&gt;'' (μM)&lt;ref name=&quot;pmid27216487&quot;&gt;{{cite journal |author1=Rickli A. |author2=Moning O. D. |author3=Hoener M. C. |author4=Liechti M. E. |title=Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens |doi=10.1016/j.euroneuro.2016.05.001 |pmid=27216487 |volume=26 |issue=8 |year=2016 |journal=Eur Neuropsychopharmacol |pages=1327–37|url=http://edoc.unibas.ch/53326/1/20170117174852_587e4af45b658.pdf }}&lt;/ref&gt;
|-
| 5-HT&lt;sub&gt;1A&lt;/sub&gt;
| 0.075
|-
| 5-HT&lt;sub&gt;2A&lt;/sub&gt;
| 0.237
|-
| 5-HT&lt;sub&gt;2C&lt;/sub&gt;
| 0.424
|-
| D&lt;sub&gt;1&lt;/sub&gt;
| 6
|-
| D&lt;sub&gt;2&lt;/sub&gt;
| 3
|-
| D&lt;sub&gt;3&lt;/sub&gt;
| 6.3
|-
| α&lt;sub&gt;1A&lt;/sub&gt;
| 1.3
|-
| α&lt;sub&gt;2A&lt;/sub&gt;
| 2.1
|-
| TAAR&lt;sub&gt;1&lt;/sub&gt;
| 2.2
|-
| H&lt;sub&gt;1&lt;/sub&gt;
| 0.22
|-
| SERT
| 6
|-
| DAT
| 22
|-
| NET
| 6.5
|}

==Society and culture==

===Black market===
[[Construction of electronic cigarettes|Electronic cigarette cartridges]] filled with DMT started to be sold on the black market in 2018.&lt;ref&gt;{{cite news |last1=Black |first1=Lester |title=New on the Black Market: Vape Pens Full of DMT |url=https://www.thestranger.com/features/2018/08/15/30763161/new-on-the-black-market-vape-pens-full-of-dmt |work=The Stranger |language=en}}&lt;/ref&gt;&lt;ref&gt;{{cite web |title=What You Need to Know About Using DMT in a Vape Pen |url=https://www.vaporvanity.com/dmt-vape-pens/ |website=Vapor Vanity |date=13 May 2019}}&lt;/ref&gt;&lt;ref&gt;{{cite web |title=DMT vape pens help bring world's strangest drug into everyday life |url=https://www.therooster.com/blog/dmt-vape-pens-help-bring-worlds-strangest-drug-into-everyday-life |website=Rooster Magazine |language=en}}&lt;/ref&gt;

==See also==
* [[DMT-N-oxide]]
* [[Psilocin]]
* [[List of psychoactive plants]]
* [[Neurotransmitter]]
* [[Psychedelic drug]]
* [[Serotonergic psychedelic]]
* [[Alexander Shulgin]]
* [[Rick Strassman]]

==References==
{{Reflist|30em}}

==External links==
{{commons category|Dimethyltryptamine}}
* [http://www.erowid.org/library/books_online/tihkal/tihkal06.shtml DMT chapter from ''TiHKAL'']
* St John, Graham. 2015. [https://www.academia.edu/16493981/Mystery_School_in_Hyperspace_Chapter_1_DMT_-_An_Enigma_Wrapped_in_a_Mystery_NAB_Evolver_2015_ ''Mystery School in Hyperspace: A Cultural History of DMT.''] Berkeley, CA.: North Atlantic Books. {{ISBN|978-1583947326}}.

{{Hallucinogens}}
{{Tryptamines}}
{{Neurotransmitters}}
{{Serotonin receptor modulators}}
{{Monoamine releasing agents}}
{{Sigma receptor modulators}}
{{TiHKAL}}

{{DEFAULTSORT:Dimethyltryptamine}}
[[Category:Ayahuasca]]
[[Category:Entheogens]]
[[Category:Tryptamine alkaloids]]
[[Category:Psychedelic tryptamines]]
[[Category:Serotonin receptor agonists]]
[[Category:Dimethylamino compounds]]
[[Category:Soft drugs]]</text>
      <sha1>0ov3b5tlx3q9raxuonizmk347yjhjwo</sha1>
    </revision>
  </page>
